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Laboratory investigation in the absence of primary reference standards is often required in forensic 
and clinical drug analysis for the following reasons. The standards for new drugs, metabolites, design-
er drugs or rare substances may not be obtainable within a reasonable period of time or their avail-
ability may also be hindered by extensive administrative requirements. Standards are usually costly 
and may have a limited shelf life. Finally, many compounds are not available commercially and some-
times not at all. A new approach within forensic and clinical drug analysis involves identifi cation based 
on accurate mass measurement and quantifi cation with a specifi c detector possessing equimolar re-
sponse to nitrogen. Formula-based identifi cation relies on the fact that the accurate mass of an ion 
from a chemical compound corresponds to the elemental composition of that compound. Single-cal-
ibrant quantifi cation is feasible with a nitrogen-specifi c detector since approximately 90% of drugs 
contain nitrogen.
For qualitative analysis, reversed-phase liquid chromatography coupled with time-of-fl ight mass 
spectrometry (LC-TOFMS) was applied with an electrospray ionisation (ESI) source operated in posi-
tive ion mode. Two types of TOFMS instrumentation were in use, applying an m/z range of 100-750 
(Applied Biosystems Mariner) or 50-800 (Bruker micrOTOF). For quantitative analysis, liquid chroma-
tography coupled with chemiluminescence nitrogen detection (LC-CLND) was applied using caffeine 
as a single secondary standard.
A method was developed for toxicological drug screening in 1 ml urine samples by LC-TOFMS. 
Sample preparation consisted of enzyme hydrolysis of glucuronide conjugates and subsequent solid-
phase extraction on a mixed-mode sorbent. A large target database of exact monoisotopic masses 
was constructed, representing the elemental formulae of reference drugs and their metabolites. Iden-
tifi cation was based on matching the sample component’s measured parameters with those in the 
database, including accurate mass and retention time (RT), if available. In addition, micrOTOF applied 
SigmaFitTM, a numerical value for isotopic pattern match. Data post-processing software was devel-
oped for automated reporting of fi ndings in an easily interpretable form. For routine screening prac-
tice, a SigmaFit tolerance of 0.03 and a mass tolerance of 10 ppm were established. Differences in 
ion abundance in urine extracts did not affect the accuracy of the automatically acquired SigmaFit or 
mass values. The limit of detection, determined for 90 compounds with Mariner, was <0.1 mg/l for 
73% of the compounds studied and >1.0 mg/l for 6% of the compounds.
Seized drug samples were analysed blind by LC-TOFMS and LC-CLND, using a “dilute and shoot” 
approach, and results were compared to accredited reference methods. In the quantitative analysis of 
amphetamine, heroin and cocaine fi ndings, the mean relative difference between the results of LC-
CLND and the reference methods was 11% (range 4.2-21%), without any observable bias. The mean 
relative standard deviation for three parallel LC-CLND results was 6%.
Liquid-liquid extraction recoveries for basic lipophilic drugs were established by LC-CLND in blood 
specimens spiked with the respective reference substances. The mean recovery by butyl chloride-iso-
propyl alcohol extraction for plasma and for whole blood was 90 ± 18% and 84 ± 20%, respectively. 
The validity of the generic extraction recovery-corrected single-calibrant LC-CLND was then verifi ed 
with profi ciency test samples. The mean accuracy was 24% and 17% for plasma and whole blood 
samples, respectively, and the maximum error was 31% for both specimens. All results by LC-CLND 
fell within the confi dence range of the reference concentrations. To demonstrate the method’s fea-
sibility, metabolic ratios for the opioid drug tramadol were determined in a pharmacogenetic study 
setting. Four volunteers were given a single 100 mg oral dose of tramadol, and a blood sample was 
collected from each subject one hour later. Extraction recovery estimation was based on model com-
pounds chosen according to their similar physicochemical characteristics (RT, pKa, log D). The mean 
differences between the results of the LC-CLND and the reference method for tramadol, O-desmeth-
yltramadol and nortramadol were 8%, 32% and 19%, respectively. 
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The LC-TOFMS method allowed effi cient urine drug screening with an automated target database 
reverse search, based on exact mass, isotopic pattern, and RT. The hit lists generated from complex 
data were simple and minimised the need for interpretation. Isotopic patterns, expressed as SigmaFit, 
revealed the true-positive fi ndings and yielded on average 12% fewer false-positive entries than 
using accurate mass only. The automated acquisition of correct SigmaFit values and accurate masses 
were proven over a wide dynamic range, the mean mass error being only 2.5 ppm by micrOTOF. The 
combination of LC-TOFMS and LC-CLND offered a simple solution for the analysis of scheduled and 
designer drugs in seized material, independent of the availability of primary reference standards. In 
blood specimens, LC-CLND analysis, corrected for extraction recovery, produced suffi ciently accurate 
results to be useful in a clinical context.
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1. INTRODUCTION
Pharmaceuticals and drugs are an omnipresent 
factor of modern society, having connections 
to the economy, pharmacotherapy, substance 
abuse, drug enforcement and crime. A number 
of scientifi c and business areas are dedicated to 
the analysis and control of drug-like substanc-
es. Forensic toxicology is a science that gener-
ates chemical and toxicological evidence for the 
administration of justice mainly in the following 
areas: post-mortem toxicology related to cause-
of-death investigations, driving under the infl u-
ence of alcohol or drugs, drug-facilitated and 
drug-related crime, and drug testing at work-
place. Forensic analysis of seized drugs is one of 
the duties of criminalistics and customs labora-
tories. Doping control in sports concerns sub-
stances on the prohibited list of the World An-
ti-Doping Agency (WADA). In clinical toxicology, 
the focus is on the diagnosis and treatment of 
the poisoned patient. All of the above disciplines 
involve similar target substances and related an-
alytical methodologies. The techniques increas-
ingly common in current drug analysis are based 
on liquid chromatography (LC), which allows the 
separation of a wide range of drugs, including 
polar and involatile compounds, and mass spec-
trometry (MS), which allows identifi cation based 
on molecular mass and characteristic fragmenta-
tion (Van Bocxlaer 2005, Maurer 2007). 
Chemical analysis measuring indirect observ-
able properties relies largely on the use of refer-
ence standards. Analytical methods that are “ra-
tio-based”, i.e. require instrumental comparison 
with calibrants of a known quantity of the ana-
lyte, use high-purity, well-characterised primary 
reference standards (PRS) or species as their basis 
for calibration. These standards can be used ei-
ther directly or through gravimetrically prepared 
calibration solutions (May et al. 2000). Second-
ary reference standards are calibrated by com-
paring with PRS using a high precision compara-
tor and making appropriate corrections for non-
ideal conditions of measurement. While the re-
quirement for using PRS is obvious in quantita-
tive analysis, these standards are the preferred 
reference in qualitative analysis, too.
The effi cient operation of forensic and clini-
cal laboratories is dependent on having an ex-
tensive collection of PRS on illicit and therapeu-
tic drugs and their metabolites, as well as pes-
ticides, household and industrial chemicals and 
other toxicologically relevant compounds. The 
number of substances required can range from 
a few hundred to a few thousand entries. So far, 
no domestic or international body has been able 
to provide the laboratories even with the most 
important substances, not to mention regular-
ly updating them with recently launched drugs. 
Unfortunately, it is the task of the individual lab-
oratories to acquire the reference substances in 
one of the following ways: purchasing them from 
commercial producers, requesting them as a gift 
from pharmaceutical companies or from anoth-
er laboratory or scientist, or producing them by 
purifi cation from seized materials. Synthesizing 
substances in the laboratory itself is only reason-
able in isolated cases. The purchase price for a 
drug metabolite can be EUR 1500-2000 for 50 
mg, and due to administrative requirements, the 
average delivery time for a reference substance is 
one to three months. In some cases, the material 
is not available at all.
Current progress in instrumental analysis 
promises to play a prominent role in compen-
sating for the availability problems of reference 
standards. While nuclear magnetic resonance 
spectrometry (NMR) is too complicated for prac-
tical analytical toxicology, certain forms of MS 
technology offer a straightforward route to what 
is a fundamental property of every molecule: ac-
curate molecular mass. Several MS techniques, 
including magnetic sector MS, Fourier transform 
ion cyclotron resonance MS (FTMS) and time-of-
fl ight MS (TOFMS), are capable of performing 
accurate mass measurement (Bristow and Webb 
2003). From suffi ciently accurate mass, a molec-
ular formula can be generated that, in turn, al-
lows the assignment of candidates for substance 
identifi cation. LC coupled with electrospray-ioni-
sation orthogonal-acceleration TOF (LC-TOFMS) 
is a particularly promising technique in the accu-
rate mass determination of components of com-
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plex mixtures (Fang et al. 2003).
Quantitative analysis requires an LC detector 
capable of producing a more consistent response 
over a broad range of structures than the custom-
ary UV detector. Universal LC detectors include 
the evaporative light scattering detector (ELSD) 
(Yurek et al. 2002) and the corona charged aer-
osol detector (CAD) (McCarthy 2005). Chemilu-
minescence nitrogen detection (CLND), however, 
represents a unique approach for quantifi cation 
of nitrogenous substances without PRS, because 
the detector possesses an equimolar response to 
nitrogen (Taylor et al. 1998). This is particularly 
valuable in human toxicology and forensic sci-
ence since approximately 90% of drugs contain 
nitrogen.
The present thesis investigates the use of LC-
TOFMS for the identifi cation and LC-CLND for 
the quantifi cation of drugs and metabolites in bi-
ofl uids and seized material, especially emphasiz-
ing analysis without PRS. The results are evaluat-
ed in the contexts of forensic and clinical toxicol-
ogy and criminalistics.
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2. REVIEW OF THE LITERATURE
2.1. Forensic and clinical drug 
analysis    
     
2.1.1. Areas of analysis
Comprehensive screening analysis plays a key 
role in various fi elds of toxicology and forensic 
science (Maurer 2004). Optimal analytical per-
formance is required in post-mortem toxicology 
laboratory practice related to cause-of-death in-
vestigations because of the wide scope of rel-
evant toxicants, the multitude of specimens, 
sometimes severely putrefi ed, and the complex-
ity of interpretation issues (Kugelberg and Jones 
2007, Drummer 2007). High demands are al-
so placed on clinical forensic toxicology, which 
covers the investigation of the toxicological as-
pects of violent crime, drug-facilitated crime, 
child welfare, drug use and drug traffi cking (Le-
Beau 2008). Identifi cation and quantifi cation of 
a wide variety of scheduled drugs in seized ma-
terial is a duty of forensic science and customs 
laboratories (Pihlainen et al. 2003), with a strong 
current emphasis on drug profi ling (Weyermann 
et al. 2008).
Controlling driving under the infl uence of al-
cohol or drugs (Walsh et al. 2004) is limited to 
agents that impair driving performance, yet this 
involves a large variety of substances. Doping 
control in sports focuses on the substances on 
the prohibited list of the WADA and is contin-
ually challenged by the emergence of new po-
tential doping agents (Thevis et al. 2008). Drug 
testing at the workplace, military, prisons and 
schools (Lillsunde et al. 2008) is usually restricted 
to illicit drugs, such as amphetamines, cannabis, 
cocaine, heroin and phencyclidine, with supple-
mental therapeutic drugs that have the poten-
tial for abuse, such as benzodiazepines. Medical 
treatment of poisoned patients at the emergen-
cy department would also benefi t from a com-
prehensive drug screening service (Fabbri et al. 
2003), but toxicological analysis in hospitals is 
usually limited to rapid immunoassay techniques, 
due to the time requirement of approximately 
two hours. Therapeutic drug monitoring refers 
to the quantitative analysis of patient plasma lev-
els in order to achieve optimal drug therapy and 
avoid overdose (Saint-Marcoux et al. 2007).
The diversity of application fi elds and goals 
suggests that there is no single method or tech-
nique best able to deal with all forensic and clini-
cal drug analyses (Smith et al. 2007). Neverthe-
less, apart from target analyses dedicated to in-
dividual key substances, a general objective has 
always been to develop comprehensive and uni-
versal analytical methods producing maximum 
information in a single run (Drummer 1999). 
However, the choice of method is fundamentally 
dependent on the specimen to be analysed and 
on the sample preparation involved.
2.1.2. Specimen considerations
The reliability and relevance of analytical toxicol-
ogy results is determined by the nature and in-
tegrity of the specimens submitted for analysis 
(Flanagan et al. 2005). Screening analysis is of-
ten performed in urine, because the time-win-
dow of detection is longer in urine than in blood. 
A sole urine sample may suffi ce in some areas of 
analytical toxicology, such as in drug testing and 
clinical toxicology. Blood concentration refl ects 
best the acute action of a substance, and con-
sequently, extensive compilations of therapeutic, 
toxic and lethal drug concentrations have been 
published for blood, plasma and serum (Schulz 
and Schmoldt 2003). Blood sampling is neces-
sary if the level of intoxication is to be studied. 
Lipophilic compounds exist in urine mainly 
as metabolites, which are more hydrophilic than 
the parent compound and thus more readily ex-
creted via the kidneys. Phase I metabolism com-
monly involves oxidation, reduction and hydrol-
ysis, while phase II metabolism involves conju-
gation reactions, especially glucuronidation and 
sulphation. For hydrophilic compounds that are 
not metabolised, the concentrations are usually 
high in urine. A cut-off concentration differenti-
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ating a positive from a negative fi nding should 
be specifi ed particularly for drugs-of-abuse in 
drug testing programs (Lillsunde et al. 2008). Ex-
act urine drug concentrations usually have a very 
limited interpretative value, except at the vicinity 
of the cut-off value. The cut-off is an administra-
tive value not necessarily equal to the analytical 
limit of detection (LOD) or limit of quantifi cation 
(LOQ). The cut-off value established will subse-
quently determine the time-window of detection 
after drug exposure (Reiter et al. 2001, Verstra-
ete 2004).
Although blood and urine are the most im-
portant specimens for toxicological drug analy-
sis, other materials, such as hair, saliva, sweat 
and meconium are also commonly used (Dolan 
et al. 2004). In post-mortem toxicology, the vitre-
ous humor is a good alternative to urine, which 
is not always available. Saliva is now extensively 
used in the control of driving under the infl uence 
of drugs due to the non-invasive sampling proce-
dure. Hair is another popular material, especially 
in clinical forensic toxicology. Drugs incorporated 
in the hair can reveal past drug use even after 
several months.
2.1.3. Sample preparation
The standard handbook on analytical toxicology 
by Baselt (Baselt 2004) covers approximately 600 
relevant organic toxicants, of which about 80% 
contain nitrogen. Major drugs of abuse that do 
not contain nitrogen are few; they include gam-
ma-hydroxybutyrate and cannabinoids. Sample 
preparation for drug screening usually involves 
division of the analytes into basic and acidic frac-
tions. The basic fraction contains the most im-
portant, toxicologically relevant classes of drugs 
and pharmaceuticals, especially substances that 
act on the central nervous system (CNS), such 
as antidepressants, antipsychotics, benzodi-
azepines, opioids and stimulants. Important car-
diovascular drugs are also mostly basic in nature, 
including adrenergic beta-blocking drugs, an-
tiarrhythmics and calcium channel blockers. In 
scientifi c drug discovery, general structural de-
scriptors have been associated with drug-like-
ness (Vistoli et al. 2008). Summarising from sev-
eral sources, an average range of properties for a 
target compound of drug analysis can be estab-
lished: it is a nitrogenous, basic compound with 
a molecular mass ranging 150-500, lipophilicity 
as log P ranging 1-5, and water solubility of 50 
mg/l at pH 6.5 (Moffat et al. 2003, Baselt 2004, 
Vistoli et al. 2008).
Direct determination of drugs by chromato-
graphic analysis is usually impossible due to the 
complexity of the sample, which often demands 
a sample preparation step that is time-consum-
ing, tedious, and frequently neglected. Com-
pounds possessing phenolic or alcoholic hydroxyl 
groups exist in urine as conjugates, making a hy-
drolysis step necessary prior to extraction. These 
compounds include many toxicologically impor-
tant drugs, such as opiates, benzodiazepines and 
cannabis. Enzyme hydrolysis is commonly used, 
because acid or base hydrolysis, though rapid, 
requires harsher conditions and also produces 
unwanted reactions. Several sample prepara-
tion techniques are used for drug analysis, in-
cluding liquid-liquid extraction (LLE), supercriti-
cal-fl uid extraction (SFE), solid-phase extraction 
(SPE), solid-phase micro-extraction (SPME), liq-
uid-phase micro-extraction, and use of restrict-
ed access materials (Wille and Lambert 2007). 
Screening for hundreds of basic drugs necessi-
tates a general, universally applicable extraction 
method, instead of a series of selective target 
methods adjusted for individual compounds. For 
quantitative analysis in blood, conventional LLE 
obviously still provides the most robust perform-
ance, while simple protein precipitation prior to 
LC analysis has also been found useful (Pragst et 
al. 2004, Flanagan et al. 2006). SPE is more ame-
nable to automation, but it has a higher number 
of variables to be optimised, which may result 
in poor quantitative precision. SPE is particularly 
well suited for urine, in which cells and proteins 
are not a problem. For applying reversed phase 
or mixed mode sorbents that combine reversed 
phase and ion exchange, SPE is a good choice in 
comprehensive urine drug analysis (Decaestecker 
et al. 2003). SPME has been found to be effec-
tual in various target analyses (Pragst 2007), and 
SFE is particularly suitable in cases involving ex-
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traction from hair (Brewer et al. 2001).
Direct on-line injection methods offer the 
advantage of reducing sample preparation steps 
and enabling effective pre-concentration and 
clean-up of biological fl uids. These methods in-
volve restricted-access materials and other au-
tomated on-line SPE procedures. Emerging au-
tomated extraction-phase technologies include 
molecularly imprinted polymers, in-tube solid-
phase microextraction, and microextraction in 
a packed syringe for more selective extraction 
(Mullett 2007). Seized samples often contain a 
high proportion of the active substance and con-
sequently do not necessarily require concentrat-
ing sample work-up. However, LLE procedures 
are useful in separating impurities and adulter-
ants from active substances (King et al. 1994). 
The success of a particular extraction method 
very much depends on the subsequent analysis 
method, and this is especially true in bioanalysis, 
where endogenous background and matrix ef-
fects are a major concern.
2.1.4. Analytical techniques
In qualitative drug screening, techniques based 
on gas chromatography-mass spectrometry (GC-
MS) have long provided the best and most cost-
effective performance. This is largely due to the 
reproducible nature of the electron ionisation 
(EI) MS spectrum, allowing the construction of 
spectral libraries in-house or on an interlabora-
tory basis. Several extensive EI-GC-MS libraries, 
containing thousands or hundreds of thousands 
of spectra, are commercially available to facili-
tate broad-scale screening for organic low-mo-
lecular-weight compounds, including drugs, de-
signer drugs, poisons and pesticides. GC-MS has 
been referred to as “the gold standard” of tox-
icological analysis. This honour is mainly due to 
the strength of GC-MS in confi rming urine im-
munoassay results for drugs of abuse.
LC combined with diode array UV detection 
(LC-DAD) is a standard technique in therapeu-
tic drug monitoring, and it has also been found 
to be useful in comprehensive drug screening. 
In the development of UV spectral libraries for 
identifi cation purposes, great attention has to be 
paid to the accuracy and precision of retention 
parameters. An LC identifi cation system based 
on a 1-nitroalkane retention index standard scale 
was described for 383 toxicologically relevant 
compounds using a reversed-phase column (Bo-
gusz and Erkens 1994). Another index stand-
ard series involved drug substances as secondary 
standards (Elliott and Hale 1998). The identifi ca-
tion power of UV spectra and retention index, 
applied separately, was low, but increased sub-
stantially when the two parameters were used 
in combination (Maier and Bogusz 1995). A very 
comprehensive LC-DAD method, relying on rel-
ative retention time (RRT), included 2682 sub-
stances (Herzler et al. 2003). Although the use 
of RRT alone produced unsatisfactory identifi ca-
tion results, 1619 substances (60.4%) were un-
ambiguously identifi ed by their UV spectra only. 
This rate was increased to 84.2% by the combi-
nation of spectrum and RRT. The authors con-
cluded that LC-DAD is one of the most reliable 
methods for substance identifi cation in toxico-
logical analysis.
During the past two decades, LC-MS has 
gained increasing success in analytical toxicolo-
gy. Most of the methods developed at the begin-
ning were target analyses for a limited number 
of analytes, typically for a drug and its main 
metabolites (Hoja et al. 1997). Comprehensive 
screening methods started to appear in the sci-
entifi c literature only ten years ago for pesticides 
(Slobodnik et al.1996) and drugs (Marquet et al. 
2000). Several types of LC-MS techniques have 
been applied to drug screening, notably based 
on single or triple quadrupole, ion-trap and time-
of-fl ight (TOF) mass analysers (Maurer 2004).
Utilisation of low-resolution MS techniques 
requires that either the target analytes’ spectra 
have been recorded in the spectral libraries used 
or the analyst possesses the respective PRS for 
direct comparison. MS fragmentation patterns in 
GC-MS (Peters et al. 2003) and ion-trap multi-
ple LC-MS (Kölliker and Oehme 2004) have been 
described to aid the structural elucidation of am-
phetamines, but this approach is overly com-
plicated for everyday forensic casework. Newly 
developed software can predict mass fragmen-
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tation from chemical structure according to dif-
ferent ionisation techniques and fragmentation 
rules (Stranz et al. 2008), but these programs are 
not routinely used. 
Comprehensive library-based screening 
methods have been developed by using single 
quadrupole LC-MS with collision-induced disso-
ciation (CID) taking place in-source (Weinmann 
et al. 1999, Rittner et al. 2001, Saint-Marcoux et 
al. 2003). Typically, spectra obtained at positive 
and negative polarity were created simultane-
ously at a high and low orifi ce voltage, showing 
extensive and weak fragmentation, respectively, 
and the spectra were summed at both polarities 
to produce informative spectral libraries. As sin-
gle MS methods suffer from lack of specifi city in 
distinguishing co-eluting substances, much em-
phasis should be put on chromatographic reso-
lution. In addition, there may be diffi culty in har-
monising the CID conditions for producing re-
producible spectra (Bogusz et al. 1999).
More reliable identifi cation can be obtained 
by LC coupled to tandem MS (MS/MS) with triple 
quadrupole (Gergov et al. 2000, Weinmann et al. 
2000), hybrid quadrupole/ion-trap (Marquet et 
al. 2003), or hybrid quadrupole/TOFMS (QTOF-
MS) technology (Decaestecker et al. 2004). This 
is due to the fact that the LC-MS/MS product ion 
spectra generated by these techniques are less 
dependent on sample composition and experi-
mental settings. However, the product ion scan 
approach requires the choice of a limited number 
of ions to be monitored in the fi rst quadrupole, 
which makes a separate survey scan necessary to 
select the ions (Gergov et al. 2001b). Informa-
tion dependent acquisition (IDA) is an interesting 
approach in comprehensive screening analysis by 
LC-MS/MS. It consists of three steps – acquisition 
of survey data, selection of the parent ions of in-
terest by abundance, and monitoring the prod-
uct ion spectra – all in a single run. IDA was fi rst 
described using a QTOF-MS instrument, without 
actually utilizing accurate mass measurement, 
however, (Decaestecker et al. 2000, Decaesteck-
er et al. 2004), and later applied by others using 
quadrupole/ion-trap instruments (Marquet et al. 
2003, Mueller et al. 2005). A major advantage 
of IDA is high specifi city and selectivity of analy-
sis, but problems may arise with variable back-
ground noise, resulting in diffi culties in setting 
the abundance threshold for acquisition.
The reproducibility of LC-MS/MS spectra be-
tween various brands of instruments has often 
been questioned. Several methods for stand-
ardising libraries of spectra have been investi-
gated between various brands or techniques, 
including triple quadrupole instruments (Ger-
gov et al. 2004), hybrid quadrupole/ion-trap in-
struments (Mueller et al. 2005) and many types 
of LC-MS/MS instruments (Bristow et al. 2004). 
In a recent interlaboratory study, the spectra of 
48 compounds were recorded on eleven mass 
spectrometers, including six ion-traps, two tri-
ple quadrupoles, a hybrid triple quadrupole, and 
two QTOF-MS instruments (Hopley et al. 2008). 
The reproducibility of the product ion spectra 
was increased when considering the tandem-in-
time instruments and the tandem-in-space in-
struments as two separate groups. A more lim-
ited screening library was proposed for LC-MS/
MS identifi cation using instruments of the same 
type from different manufacturers (Hopley et al. 
2008). Both MS/MS product ion spectra and in-
source-CID-MS spectra have been made com-
mercially available, but thus far they have found 
little use compared to the success of EI-GC-MS 
libraries.
Another mode of analysis within LC-MS/MS 
that has been applied to screening analysis is 
multiple reaction monitoring (MRM). It is a more 
sensitive mode of operation and amenable to 
quantifi cation, but there is also a technical lim-
it to the number of target compounds that can 
be monitored by MRM-type experiments, which 
hinders the utility of this approach in compre-
hensive screening. A qualitative screening meth-
od for up to 238 drugs has been published us-
ing MRM (Gergov et al. 2003), but usually MRM 
methods comprise much fewer compounds.
The advantages and disadvantages of LC-MS 
screening methods are much related to the com-
monly used ionisation techniques, atmospher-
ic pressure chemical ionisation (APCI) and elec-
trospray ionisation (ESI) (Fenn et al. 1990, Bru-
ins 1991). Both are soft ionisation techniques 
that do not produce much fragmentation. Vol-
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atile buffers are required for chromatography, 
which limits the optimisation of separation by 
the modifi cations of mobile phase. Neither tech-
nique is universal for all types of compounds, al-
though ESI possesses a broader applicability in 
drug analysis due to its suitability for polar com-
pounds. Unfortunately, there is always the risk of 
detrimental ion suppression, particularly with ESI 
(Dams et al. 2003), and consequent false nega-
tive fi ndings in comprehensive screening analy-
sis, where matrix effects cannot be controlled for 
the numerous target compounds included in the 
screen.
Simultaneous screening and quantifi cation is 
viable mainly when using techniques allow quan-
titative calibrations to be performed only infre-
quently, i.e. on a weekly or monthly basis, such 
as by GC with nitrogen-selective detection (Ras-
anen et al. 2003) or by LC with diode-array UV 
detection (Pragst et al. 2004). A limit of 100-200 
compounds is the maximum in such methods in 
order to maintain both qualitative and quantita-
tive precision in practical work. Evidently, preci-
sion of the chromatographic retention parame-
ter plays a more prominent role in GC- and LC-
based methods than in the MS-based methods 
discussed above. For analytic techniques that 
need quantitative calibration in each sequence 
of runs, especially GC-MS and LC-MS, the meth-
ods used have typically consisted of only 10-20 
compounds. However, a quantitative method has 
been developed for up to 100 pesticides in food 
with triple quadrupole LC-MS/MS, using a sim-
plifi ed calibration scheme (Ferrer et al. 2007).
2.2. Analysis without primary 
reference standards   
     
2.2.1. Availability of standards
Analysis of drugs is hindered by the lack of read-
ily available PRS, which are required when using 
techniques in which identifi cation and quantifi -
cation are based on comparison of chromato-
graphic retention, spectra and detector response 
between the analyte and the standard. While 
extensive collections of spectral and chromato-
graphic data are available for common drugs 
(Herzler et al. 2003, Moffat et al. 2003), prob-
lems arise when rare and new substances ap-
pear on the continually changing drug scene. 
The term designer drug originated in connection 
with the epidemic of unscheduled fentanyl ana-
logs in California during the 1980s (Henderson 
1988). Stricter analog legislation in the US since 
1986 probably prompted the relocation of de-
signer drug production, largely to Europe. The 
following chemical classes are prominent among 
the drugs encountered: amphetamines (Peters et 
al. 2003), fentanyls (Ohta et al. 1999), pipera-
zines (de Boer et al. 2001, Peters et al. 2003), 
pyrrolidinopropiophenones (Springer et al. 2003) 
and tryptamines (Shulgin 2003).
Another area of research that suffers from 
the lack of PRS is metabolite analysis. With many 
drugs, such as heroin and cocaine, the metabo-
lites are the main proof of illicit drug intake (Jones 
et al. 2008). In blood, the ratio of parent drug to 
metabolite is instrumental in estimating the time 
of administration, in differentiating between acute 
vs. chronic exposure and in studying pharmacoge-
netic aspects. Metabolite fi ndings in urine are also 
helpful in confi rming drug screening results. Find-
ing a metabolite in hair can verify that the corre-
sponding drug has been ingested, if external con-
tamination had been suspected instead.
PRS for certain drugs and metabolites are 
available from commercial, governmental and in-
ternational sources. However, their delivery time 
is lengthy, normally ranging from several weeks 
to several months. Moreover, the cost of stand-
ards is further increased by the extensive admin-
istrative requirements imposed on the importa-
tion or exportation of controlled substances. In 
many cases, PRS are not commercially available. 
The considerable effort required for synthesising 
PRS in-house is justifi ed in important research-
oriented projects. This is exemplifi ed with the 
synthesis of amphetamine impurities for the de-
velopment of a harmonised method for profi ling 
amphetamines (Aalberg et al. 2005) and with 
the synthesis of steroid metabolites for predict-
ing the metabolic patterns of new derivatives of 
anabolic androgenic steroids for doping control 
purposes (Kuuranne et al. 2008).
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Apart from designer drugs and metabolites, 
it may even be problematic to acquire a PRS for a 
newly launched prescription drug because of the 
ever-increasing cost of drug development and 
the subsequent reluctance of the manufacturer 
to release the standard. Forensic and toxicologi-
cal investigations are by nature prone to produce 
undesirable results by revealing trends of poison-
ings that may threaten the market share of the 
drug. The history of forensic toxicology recog-
nises a number of prescription drugs that have 
been found to be associated with abuse or an 
excess of fatal poisonings, such as dextropropox-
yphene (Hudson et al. 1977), barbiturates (Stead 
and Moffat 1983), tricyclic antidepressants (Hen-
ry 1989), buprenorphine (Tracqui et al. 1998), 
venlafaxine (Koski et al. 2005) and tramadol (Tjä-
derborn et al. 2007).
2.2.2. Identification by accurate 
mass measurement
In the 1950s, Beynon explained for the fi rst time 
that if the mass of an ion from a chemical com-
pound is determined with suffi cient accuracy, 
the elemental composition of that compound 
could be deduced (Beynon 1954). Mass accura-
cy is the difference between the theoretical val-
ue of the mass of an ion and the mass measured 
using a mass spectrometer. The resolving power 
of a mass spectrometer is defi ned as the capacity 
to separate ions of adjacent m/z, and resolution 
is the measure of the separation of the two mass 
spectral peaks. Resolution is usually defi ned in 
one of two ways, depending on the mass spec-
trometer being used (Figure 1). The 10% valley 
(intensity) defi nition used with magnetic sector 
instruments states that two peaks of equal inten-
sity are considered to be resolved when they are 
separated by a valley, which is 10% of the height 
of each peak. The defi nition used with quadru-
pole, Fourier transform ion cyclotron resonance, 
ion-trap and time-of-fl ight mass spectrometers is 
based on a peak width measured at 50% peak 
height (full width at half maximum or FWHM), 
producing a value approximately double that cal-
culated using the 10% valley defi nition (Bristow 
2006). The better the accuracy, the less the am-
biguity in molecular formula determination. 
With increasing m/z, the number of formulae fi t-
ting a measured molecular mass will increase un-
til it becomes impossible to obtain an unambigu-










Figure 1. Two ways of defi ning the mass resolution: the 10% valley defi nition and the full width 
at half maximum (FWHM) defi nition.
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For many years since the discovery of the ac-
curate mass concept, measurements were only 
carried out using magnetic-sector MS. The avail-
ability of such measurements was limited due to 
the cost and complexity of the instrumentation 
and the need for considerable expertise to acquire 
and interpret the spectra (Bristow 2006). Already 
in the 1970s, accurate mass was utilised for moni-
toring specifi c compounds in environmental and 
biological samples with packed-column (Kimble 
et al. 1974, Ehrenthal et al. 1977) and capillary 
column GC coupled to high-resolution double-
focusing magnetic-sector MS (GC-HRMS) (Burl-
ingame 1977, Lewis et al. 1979). Still today, the 
GC-HRMS technique is in use in certain demand-
ing applications, such as in investigating human 
exposure to dioxins and PCB compounds (Tuomis-
to et al. 2006). Using the peak matching mode, 
an accuracy of <1 ppm can be achieved, but the 
reference mass should be as close as possible to 
the analyte mass, thus excluding broad-spectrum 
mass screening (Bristow and Webb 2003).
Single-quadrupole and triple-quadrupole MS 
are inherently low-resolution instruments. How-
ever, accurate mass measurements (<5 ppm) can 
be obtained after careful calibration in a narrow 
m/z range and when no unresolved interferenc-
es are present at the masses of interest (Tyler et 
al. 1996). This was emphasised in an interlabora-
tory comparison where both of the participating 
laboratories using triple-quadrupole instruments 
reported a mean measurement accuracy of <2 
ppm (Bristow and Webb 2003).
Recently, a novel hybrid mass spectrometer 
was described. It couples a linear ion-trap mass 
spectrometer to an orbitrap mass analyser via a 
radio-frequency-only trapping quadrupole with 
a curved axis. The instrument provided high res-
olution and high-accuracy mass measurements, 
within 2 ppm using internal standards and with-
in 5 ppm with external calibration (Makarov et 
al. 2006). However, the total MS cycle time was 
highly dependent on mass resolution; i.e., the 
higher the mass resolution, the higher the cycle 
time. For example, a mass resolution of 100,000 
(FWHM) resulted in a cycle time of about 2 s. 
This excludes the use of ultra high-performance 
LC separations, because there will not be enough 
data points over a chromatographic peak (Ho-
genboom et al. 2008).
The ultimate mass measurement technique 
is FTMS, which provides very high mass accura-
cy (<1 ppm) and mass resolving power (Amster 
1996, Marshall et al. 1998, Bristow and Webb 
2003) as well as high sensitivity in the attomole 
and even in the zeptomole range (Belov et al. 
2000). The high mass accuracy of FTMS has been 
































Figure 2. Relation of mass accuracy and the number of possible elemental formulae at three dif-
ferent molecular weights.
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strategy in proteomics to detect proteins using 
exact masses of protein tryptic digests (Smith et 
al. 2002). Results obtained in toxicology have 
shown that very accurate masses can dramatical-
ly improve confi dence in identifying compounds 
using a database search (Ojanperä et al. 2005).
Accurate mass determination with moderate-
ly good resolution became feasible on a routine 
basis with the development of orthogonal accel-
eration TOFMS analysers (Dawson and Guilhaus 
1989), and modern instruments can readily be 
combined with LC using an ESI ion source (Mir-
gorodskaya et al. 1994). Affordable benchtop 
LC-TOFMS instruments have found widespread 
use in the analysis of small molecules, such as in 
drug bioanalysis (Zhang et al. 2000a) and in high-
throughput screening for combinatorial chemis-
try libraries (Fang et al. 2003). Emerging TOFMS 
technology, resulting in continual improvements 
in mass accuracy, resolution and other analyti-
cally important features, has greatly diminished 
the development of magnetic-sector MS (Guil-
haus et al. 2000). A key concept of the present 
thesis involves a LC-TOFMS urine drug screening 
method that essentially relies on accurate mass 
measurement combined with an automated for-
mula-based target database search (Gergov et 
al. 2001a). A detailed discussion of LC-TOFMS is 
included in Section 2.4.
2.2.3. Isotopic pattern in 
identification
In addition to accurate mass, isotopic pattern 
is a property that can be utilised in substance 
identifi cation. Many elements have typical iso-
tope patterns, allowing the number of possible 
elemental formulae to be reduced. The follow-
ing elements have distinctive patterns: chlorine 
(35Cl:37Cl ~ 3:1), bromine (79Br:81Br ~ 1:1) and 
sulphur (32S:33S:34S ~ 100:1:4). The carbon iso-
tope ratio (12C:13C ~ 100:1.1) can be used to cal-
culate the number of carbon atoms in the mol-
ecule. An ion containing 10 carbon atoms will 
have a 13C isotope peak with an abundance of 
11% of the 12C peak and an ion containing 50 
carbon atoms will have a 13C isotope peak with 
an abundance of 55% of the 12C peak (Bristow 
2006). The calculation of abundance patterns re-
sulting from the combination of more than one 
polyisotopic element becomes more complex. 
Matching of the theoretical calculated isotop-
ic pattern against the measured pattern plays a 
key step in revealing the correct elemental com-
position from a mass spectrum (Rockwood and 
van Orden 1996). The idea was discovered years 
ago and has proven useful for structure elucida-
tion using low-resolution mass spectra (Kavan-
agh 1980, Tenhosaari 1988, Palmer and Enke 
1989). However, prior to the present thesis, the 
use of isotopic patterns as a numerical identifi ca-
tion parameter has not been investigated in the 
context of drug screening.
2.2.4. Quantification
While qualitative analysis without PRS can lean 
on accurate mass measurement, spectral and 
chromatographic libraries and ultimately on NMR 
spectrometry, quantifi cation has been very much 
dependent on PRS. Thus, maintaining an up-to-
date collection of hundreds of standards is a te-
dious and expensive duty of forensic and clinical 
laboratories. Determination of blood drug con-
centrations is a necessity for the evaluation of 
whether a person has been under the infl uence 
of a substance. In forensic science, quantitative 
information on the purity of illegal drugs is used 
for various purposes, including valuation for sen-
tencing, profi ling and sample comparison, in ad-
dition to use in studies on the economics of the 
illicit market (King 1997). 
There are few analytical techniques capa-
ble of accurate quantifi cation without PRS. An 
important approach is quantifi cation by proton 
counting with NMR. The electronic reference to 
access in vivo concentrations (ERETIC) method in 
NMR was introduced as a way of determining 
absolute concentrations (Barantin et al. 1997). 
An artifi cial radio frequency reference ERETIC 
signal produced with rigorously controlled pa-
rameters is added to the observed NMR sample 
spectrum. This eliminates handling and contami-
nation issues associated with internal standards, 
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allowing quantifi cation of protons with respect 
to the ERETIC signal. High accuracy and precision 
was obtained with the ERETIC method in NMR, 
referred to as a “gold standard” of quantifi ca-
tion (Lane et al. 2005, Lane et al. 2006). How-
ever, this technique is beyond the scope of most 
forensic and clinical laboratories.
In GC, the concept of effective carbon 
number is a model by which the fl ame ionisation 
response of compounds can be predicted, and 
it has been utilised for cannabinoids (Poortman-
van der Meer and Huizer 1999) and ampheta-
mine-type compounds (Huizer et al. 2001). Us-
ing individually selected secondary standards for 
each type of stimulant, the error of prediction 
was generally less than 5% (Huizer at al. 2001). 
In combinatorial chemistry related to drug 
discovery, the characterisation of synthesis prod-
ucts, without possessing PRS, has become feasi-
ble via utilisation of special detectors, such as the 
evaporative light scattering detector (ELSD) (Fang 
et al. 2000) or the chemiluminescence nitrogen 
detector (CLND) (Taylor et al. 1998, Yurek et al. 
2002, Yan et al. 2003). ELSD (Ford and Kennard 
1966) is an excellent quantitative detector when 
calibrated in an analyte-specifi c manner. LC-ELSD 
detects all compounds that are less volatile than 
the mobile phase, and it is commonly used for 
compounds without a UV chromophore, such 
as carbohydrates, lipids and polymers. ELSD can 
therefore offer advantages over conventional UV 
or refractive index detection, particularly for gra-
dient separations. The general detection mech-
anism of ELSD involves a three-stage process: 
nebulisation, evaporation, and detection. The 
aerosol formed enters a heated evaporator tube, 
where the mobile phase is evaporated, leav-
ing a dry particle plume. The dry particles com-
ing out from the tube are irradiated by a light 
source, and the scattered light from the parti-
cles is detected. The quantity of light scattered 
by the particles is dependent on the concentra-
tion of the analyte, and the ELSD response is re-
lated to the absolute quantity of the compound 
independently of its optical properties (Zhang et 
al. 2008). Careful choice of standards could limit 
errors to 10–20% for limited sample sets (Kibbey 
1996). However, larger errors occurred in cases 
where standards were less representative (Fang 
et al. 2000), and reduced ELSD response was ob-
tained from low-molecular-weight compounds 
(Hsu et al. 1999, Fang et al. 2001). ELSD was 
found to normally bias toward the underestima-
tion of chromatographically resolved impurities, 
resulting in an overestimation of analyte purity 
(Lane et al. 2005)
Another universal detector, the corona 
charged aerosol detector (CAD), was fi rst devel-
oped in 2004 (Paschlau 2005), but little critical 
scientifi c literature is available on this instrument 
yet (Gorecki et al. 2006, Brunelli et al. 2007). In 
LC coupled to corona CAD, the mobile phase 
is nebulised with nitrogen and the droplets are 
dried, producing analyte particles. A stream of 
nitrogen becomes positively charged as it pass-
es a high-voltage platinum corona wire, and this 
charge is transferred to the opposing stream of 
analyte particles. The charge is then measured 
at a collector, generating a signal with an inten-
sity that is proportional to the quantity of an-
alyte. Corona CAD is more sensitive than ELSD 
and has a wider dynamic range; it also allows 
the use of a wider variety of mobile phases and 
buffers. However, as with ELSD, the response de-
pends on the composition of the mobile phase, 
with higher responses observed at higher organ-
ic contents (Zhang et al. 2008). In LC applica-
tions, a technique called mobile-phase compen-
sation can be used to solve this problem (Gorecki 
et al. 2006). A separate pump is required to com-
pensate the organic content in the mobile phase 
by delivering exactly an inversed gradient prior to 
the detection. As long as the compounds are non-
volatile, the response factors obtained on corona 
CAD are uniform independently of their nature, 
which opens the door to quantifi cation of uniden-
tifi ed species or single-compound calibration.
CLND is a detector that has already achieved 
an established position in the science of drug dis-
covery due to its equimolar response to nitrogen-
containing compounds, allowing the detector to 
be calibrated by a single secondary standard (Yan 
1999). The detector is thus a promising alterna-
tive for managing with the challenges of forensic 
and clinical drug analysis. A detailed discussion 
of LC-CLND is included in Section 2.5.
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2.3. Liquid chromatography – time-
of-flight mass spectrometry (LC-
TOFMS)
TOFMS has been commercially available since the 
late 1950s, following the publication of the de-
sign later commercialised by the Bendix Corpora-
tion (Wiley and McClaren 1955). The TOFMS is an 
attractive instrument due to its potentially unlim-
ited m/z range and high-speed acquisition capa-
bilities. However, there were several physical and 
technical limitations to the early TOFMS instru-
ments that limited their resolving power (FWHM 
300) and mass accuracy (Guilhaus et al. 1997). 
The initial spatial, temporal, and velocity distribu-
tions of ion populations can broaden the distribu-
tion of ion arrival times, hence greatly reducing 
resolving power. This has an effect on mass ac-
curacy as there is a high probability that interfer-
ing ions will not be resolved. Three major techno-
logical developments have resulted in TOFMS be-
coming capable of accurate mass measurement: 
the refl ectron, delayed extraction, and orthogonal 
acceleration (Bristow 2006). The rapid growth of 
applications involving TOFMS is due to the emer-
gence of matrix-assisted laser desorption/ionisa-
tion (MALDI) and the rediscovery of the orthogo-
nal acceleration concept (Guilhaus et al. 2000).
Off-axis or orthogonal acceleration TOFMS of 
ions from continuous ion beams has been known 
since the 1960s. It was only in the late 1980s and 
early 1990s that the current range of TOFMS in-
struments with greatly improved resolving pow-
er and mass accuracy was developed (Dawson 
and Guilhaus 1989, Guilhaus et al. 1997). The 
key features enabling accurate mass measure-
ment include high effi ciency in gating ions from 
an external continuous source (e.g. ESI, APCI), 
simultaneous correction of velocity and spatial 
dispersion, and increased mass resolving pow-
er (Bristow 2006). The digital electronics revolu-
tion has supported TOFMS more than MS tech-
nologies more heavily reliant on analog signal 
processing (Guilhaus et al. 2000). In this disser-
tation, TOFMS refers to orthogonal acceleration 
technology unless otherwise stated. A schematic 
presentation of orthogonal acceleration TOFMS 









Figure 3. A schematic presenta-
tion of an orthogonal acceler-
ation (oa) time-of-fl ight mass 
spectrometer (TOFMS).
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LC-TOFMS enables accurate mass determi-
nation of components of complex mixtures to 
be performed in a routine manner (Chernushev-
ich et al. 1997, Guilhaus et al. 1997, Eckers et 
al. 2000). In the fi eld of drug discovery, the de-
velopment of combinatorial chemistry created a 
need for rapid characterisation of the complex 
mixtures that are generated by synthesis (Yurek 
et al. 2002). Two MS techniques, LC-FTMS (Fang 
et al. 1998) and LC-TOFMS (Fang et al. 2002), 
made feasible accurate mass measurement of 
even thermally unstable and higher-molecular-
mass compounds. Currently, LC-TOFMS is the 
most cost-effective technique for performing 
accurate mass analysis of small molecules on a 
routine basis (Balogh 2004). In addition to high 
mass accuracy (<5 ppm), the benefi ts of TOFMS 
include good mass resolution (FWHM 10,000), 
wide mass range, and fast mass spectral acqui-
sition speed with high full-scan sensitivity — all 
attributes being superior to those obtained with 
a scanned quadrupole. Today, the mass accuracy 
of TOFMS is comparable to that of much more 
expensive accurate-mass instruments (Stroh et 
al. 2007), and the mass resolution can exceed 
60,000 FWHM.
LC-TOFMS-based accurate-mass methods 
have already found extensive use in many facets 
of analytical research, for example, in the struc-
ture elucidation of metabolites (Zhang 2000b, 
Nassar et al. 2003, Leclercq et al. 2005), pesti-
cides (Maizels and Budde 2001), steroids (Nielen 
et al. 2001, Nielen et al. 2007), and unknown 
compounds in environmental water (Ibanez et al. 
2005). Notably, comprehensive screening analy-
sis had not been realised until the studies of this 
thesis, mainly due to limitations in data acquisi-
tion and processing capabilities. Recently, how-
ever, an analogous multi-residue monitoring ap-
proach involving in-source CID has been pub-
lished for the analysis of pesticides and their deg-
radates in food and water samples (Ferrer and 
Thurman 2007). 
For drug screening purposes, it is very impor-
tant to be able to measure the accurate mass of 
the sample components in an automated man-
ner, without successive dilutions of the sample or 
tedious optimisations for each ion depending on 
its abundance. New generation TOFMS instru-
ments use detection systems based on analog-
to-digital converters (ADC). An advantage of this 
technology is a much increased ion-abundance 
dynamic range for accurate mass measurement. 
An alternative approach that still employs time-
to-digital technology is to defocus the ion beam, 
resulting in reduced abundance at the detector. 
Therefore, higher analyte concentrations and 
hence higher ion abundance can be measured 
at the optimum ion abundance for the detector 
(Bristow et al. 2008).
The development and commercialisation 
of hybrid QTOF-MS used a similar approach to 
orthogonal acceleration TOFMS (Morris et al. 
1996, Chernushevich et al. 2001). In a recent 
evaluation of a modern QTOF-MS instrument 
applying ADC technology, mass measurement 
accuracy remained stable, within ±0.0015 m/z 
units, over approximately 3-4 orders of magni-
tude of ion abundance. In MS/MS experiments, 
similar mass accuracy to single MS was obtained 
for product ions using only one calibration pro-
cedure. However, it was slightly reduced at low 
ion abundance (Bristow et al. 2008). These fi nd-
ings suggest that QTOF-MS is an equally feasible 
instrumentation for drug screening based on ac-
curate mass measurement.
Current TOFMS instrumentation has been 
equipped with isotopic pattern match algo-
rithms as a part of the molecular formula gen-
eration capabilities, providing an exact numeri-
cal comparison of theoretical and measured iso-
topic patterns as an additional identifi cation tool 
for accurate mass determination. In a preliminary 
study, this function was found to facilitate urine 
drug screening in distinguishing between com-
pounds with adjacent molecular masses (Laks et 
al. 2004). Later, it was shown that isotopic pat-
tern match can also be successfully used with 
MS/MS experiments using a QTOF-MS instru-
ment (Bristow et al. 2008).
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2.4. Liquid chromatography 
– chemiluminescence nitrogen 
detection (LC-CLND)
Chemiluminescent reactions have a history of 
over one hundred years, and analytical applica-
tions of chemiluminescence began to be used in 
the 1970s. The chemiluminescent reactions be-
tween ozone and various molecules have been 
exploited for detection of olefi ns, ozone, nitric 
oxide, other nitrogen oxides, organosulphur 
compounds, and a variety of other organic com-
pounds. NO+O3 chemiluminescence forms the 
basis of a large number of these applications. 
At fi rst, many of the applications were analys-
ers for a specifi c compound or reaction without 
chromatographic separation. Later, these tech-
niques were applied to the development of spe-
cialised selective detectors (Yan 1999). LC-CLND 
was fi rst described in 1988 (Robbat et al. 1988), 
and was subsequently refi ned and described in 
its current form in 1992 (Fujinari and Courthau-
don 1992). A schematic of the CLND principle 
is shown in Figure 4. Oxidation of the nebulised 
LC mobile phase by combustion in a high-tem-
perature furnace converts all nitrogen-contain-
ing compounds, except for N2, quantitatively 
into nitric oxide. The dried gas is passed into a 
chamber where it reacts with ozone, which re-
sults in the conversion of nitric oxide to excit-
ed-state nitrogen dioxide. The substance subse-
quently emits chemiluminescent light upon re-
laxation. The light amplifi ed by the photomulti-
plier tube is proportional to the moles of nitro-
gen present in a fraction analysed. All mobile-
phase components must be free of nitrogen to 
keep the baseline noise to a minimum, making 
acetonitrile, ammonium salts and nitrogenous 
bases incompatible with CLND detection (Zhang 
et al. 2008).
Figure 4. A schematic presentation of a chemiluminescence nitrogen detector (CLND) for liquid 
chromatography (LC).
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Recent improvements in CLND instrumen-
tation, including nebuliser design and ceramic 
pyrotube, have improved the robustness of the 
technique and its applicability for routine analy-
sis. In addition, when coupled with an UV detec-
tor, CLND can be used to determine relative re-
sponse factors for any nitrogen-containing com-
pound (Liang et al. 2008). Response ratios be-
tween CLND and UV detection (Nussbaum et 
al. 2002) and between CLND and MS detection 
(Deng et al. 2004) have been measured in order 
to extend the concentration range of N-equimo-
lar quantifi cation by LC-CLND.
Originally, CLND was reported to possess 
an LOD of 0.1 ng nitrogen, a nitrogen/carbon 
selectivity of 107 (Yan 1999) and, over a linear 
range of 2 orders of magnitude, an equimolar 
response with ±10% average error for the com-
pounds studied (Taylor et al. 1998). It was also 
found that the sole exception to equimolar re-
sponse of the CLND arises from chemical struc-
tures containing adjacent nitrogen atoms. A pro-
posed guideline was that the response should be 
0 when adjacent nitrogen atoms are connected 
by a double bond and 0.5 when adjacent nitro-
gen atoms are connected by a single bond. Later 
studies have shown that CLND response is high-
ly structure dependent in compounds with adja-
cent nitrogen atoms connected by a single bond. 
Substitutions on the nitrogen atoms or atoms 
nearby in the molecule can increase the CLND 
response to approach a value higher than the 
predicted value 0.5 (maximal value 0.82/nitrogen 
atom). Without substitution, much lower values 
than predicted (minimal value 0.0-0.08/nitrogen 
atom) were obtained. Thus, a structurally simi-
lar calibration compound should be used for this 
class of compounds in the quantitative analysis 
using CLND (Yan et al. 2007).
The CLND linear range of two orders of mag-
nitude was found to be insuffi cient in some ap-
plications of pharmaceutical analysis, when the 
impurities are present at much lower levels than 
the surrogate standard. The common practice of 
direct conversion of area percent to weight per-
cent can result in signifi cant errors using CLND. 
To increase quantifi cation accuracy, it was pro-
posed that a secondary dilution of the surrogate 
reference standard solution should be used for 
the quantifi cation of low-level impurities (Liang 
et al. 2008).
Single-calibrant quantifi cation by LC-CLND 
is straightforward in relatively simple materials 
requiring no extraction, such as combinatorial 
chemistry library products (Corens et al. 2004, 
Letot et al. 2005) or nitrogen-containing anions 
in seawater (Lucy and Harrison 2001). Howev-
er, there are currently very few LC-CLND applica-
tions for biological samples. In the experimental 
methods presented for rat bile and urine (Taylor 
et al. 2002), dog plasma and urine (Deng et al. 
2004) and microsomal incubations (Edlund and 
Baranczewski 2004), sample preparation relied 
on protein precipitation followed by direct LC 
injection omitting the extraction step. In meth-
ods involving protein precipitation, the occasion-
ally necessary freeze-drying may result in losses 
of volatile analytes. A benefi t from an extrac-
tion step would be a cleaner chromatographic 
background and easier sample concentration, 
but quantifi cation without PRS presumes known 
extraction recoveries. An SPE method has been 
reported for the determination of imidacloprid 
in fruit and vegetables with a relatively constant 
extraction recovery, but the study utilised CLND 
solely as a nitrogen-specifi c detector without 
taking advantage of the N-equimolar response 
(Ting et al. 2004).
CLND is a particularly attractive detector in 
the quantitative analysis of drugs, metabolites 
and designer drugs in forensic and clinical con-
texts without PRS, due to its specifi city and equi-
molar response to nitrogen. The LC version of 
the detector is more useful than the GC version, 
because it allows detection of a wide range of 
compounds without derivatisation. A major chal-
lenge is the development of sample preparation 
procedures that can minimise excessive back-




3. AIMS OF THE STUDY
The aim of this thesis work was to investigate how the qualitative and quantitative analysis of drugs 
in forensic and clinical contexts may be best performed without the necessity of possessing the re-
spective primary reference standards (PRS).
Specific aims of the studies were:
I To develop and evaluate an automated LC-TOFMS method for urine drug screening, essentially 
based on accurate mass measurement and reverse search using a large target database of monoi-
sotopic masses.
II To add isotopic pattern comparison as a new identifi cation parameter to the LC-TOFMS meth-
od.
III To apply LC-TOFMS to the identifi cation and LC-CLND to the quantifi cation of drugs in seized ma-
terial as a novel approach for instant substance characterisation without PRS.
IV To develop an LC-CLND method for the quantifi cation of basic drugs in plasma and whole blood 
without PRS.
V To evaluate the feasibility of the LC-CLND method in a pharmacogenetic context by studying plas-
ma tramadol metabolite ratios without PRS. 
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More detailed descriptions of the materials and 
methods are presented in the original publica-
tions (I-V).
4.1. Reagents
Water was Direct-Q 3 purifi ed (Millipore, Bed-
ford, MA, USA). LC mobile phase components, 
methanol and acetonitrile, were HPLC grade from 
Rathburn (Walkerburn, UK). Jeffamine D230 and 
analytical grade solvents, n-butyl chloride and 
isopropyl alcohol, were from Fluka (Buchs, Swit-
zerland). β-glucuronidase was from Roche (Man-
nheim, Germany). Other chemicals and reagents 
were analytical grade from Merck (Darmstadt, 
Germany), J.T. Baker (Deventer, The Netherlands) 
and Sigma-Aldrich (Steinheim, Germany). Isolute 
HCX-5 (100 mg) mixed-mode solid-phase ex-
traction (SPE) cartridges were from International 
Sorbent Technology (Hengoed, UK).
 
4.2. Reference standards and 
materials
Tramadol and its metabolites were a kind gift 
from Grünenthal GmbH (Aachen, Germany). 
Caffeine standards were purchased from Ultra 
Scientifi c (Wesel, Germany) and from Sigma-
Aldrich (Steinheim, Germany). Other drug ref-
erence standards were obtained from various 
pharmaceutical companies. Certifi ed reference 
serum samples for drugs were purchased from 
LGC Promochem (Teddington, UK). Reference 
whole blood samples for drugs were from the 
Nordquant profi ciency test program (Oslo, Nor-
way), involving 13 participants. Pooled blank hu-
man plasma was obtained from the Finnish Red 
Cross Blood Service, and blank whole blood was 
bovine blood from an abattoir. Blank urine was 
from various volunteer donors. Seized samples 
were obtained from the National Bureau of In-
vestigation, Finland.
4.3. Study subjects
Case urine samples were collected at autopsies 
for qualitative LC-TOFMS experiments (I, II). In 
the LC-CLND study involving tramadol (V), blood 
samples from the volunteer subjects were col-
lected in EDTA tubes one hour after administra-
tion of 100 mg of tramadol hydrochloride orally, 
and plasma was separated by centrifugation.
4.4. Methods    
     
4.4.1. Sample preparation
In LC-TOFMS urine screening experiments (I, II), 
urine samples of 1 ml were hydrolysed with β-
glucuronidase for 2 h at 56oC in a water bath. 
As an internal standard, 10 µl of dibenzepin (10 
µg/ml in methanol) was added to the hydrolysed 
samples. The extraction was performed accord-
ing to International Sorbent Technology appli-
cation note IST 1044 A (IST 1997), with minor 
modifi cations. The pH of urine samples was ad-
justed between 5 and 7 with 2 ml of 0.1 M phos-
phate buffer (pH 6). The SPE cartridge was con-
ditioned with 2 ml of methanol and equilibrat-
ed with 2 ml of water and 3 ml of 0.1 M phos-
phate buffer (pH 6). After sample addition, the 
cartridge was washed with 1 ml of phosphate 
buffer and with 1 ml of 1 M acetic acid, and af-
ter both washing steps, dried under full vacuum 
for 5 min. The acidic-neutral fraction was eluted 
with 3 ml of ethyl acetate-hexane (25+75, v/v). 
The cartridge was dried for 2 min and washed 
with 3 ml of methanol. After drying for 2 min, 
basic drugs were eluted with 3 ml of ethyl ace-
tate-ammonium hydroxide (98+2, v/v). After ex-
traction, the acidic and basic fractions were com-
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bined and evaporated to dryness at 40oC. The 
dried sample was reconstituted with 150 µl of 
acetonitrile-0.1% formic acid (1+9, v/v).
For the analysis of seized street drug sam-
ples (III), the material, which in all cases was in 
solid form, was homogenised and 1-4 mg was 
dissolved in methanol to obtain a stock solution 
of 1 mg/ml. For identifi cation, the stock solution 
was diluted 1:100 with methanol-0.1% formic 
acid (1+9, v/v). If MS response was low with the 
dilution of 1:100, the stock solution was used for 
identifi cation instead. For quantifi cation, three 
dilutions were made separately from the stock 
solution: 1:2 with methanol-0.1% formic acid 
(1+1, v/v), and 1:10 and 1:100 with methanol-
0.1% formic acid (3+7, v/v). 
For the LC-CLND quantifi cation of drugs in 
plasma and whole blood (IV) to a 5 ml sample, 
2 ml of 1 M TRIS buffer (pH 11) was added. pH 
was adjusted to 10 by 5 M sodium hydroxide. Af-
ter addition of 10 ml of n-butyl chloride-isopro-
panol (98+2, v/v), the sample was shaken for 30 
min in a rotor shaker. Following phase separation 
by centrifugation (10 min at 4000 rpm), 7.5 ml 
of the organic layer was transferred into another 
test tube and evaporated to dryness at 40ºC un-
der a gentle stream of nitrogen. The residue was 
reconstituted with 100 µl of methanol-0.1% for-
mic acid (1+1, v/v), and after vortexing and cen-
trifugation, the supernatant was transferred into 
an autosampler vial for LC-CLND analysis. 
For the LC-CLND quantifi cation of trama-
dol and its metabolites (V), 10 µl of the internal 
standard solution (0.1 mg/ml of dextropropoxy-
phene in methanol) was added to a 5 ml sam-
ple to yield a concentration of 200 µg/l. The ex-
traction procedure was similar to that in study IV 
with the following exceptions: the volume of n-
butyl chloride-isopropanol (98+2, v/v) was 7 ml, 
and 5.5 ml of the organic layer was collected. 
The evaporated residue was reconstituted with 
75 µl of methanol-0.1% formic acid (2+8, v/v).
In all quantitative studies, caffeine stock so-
lutions were diluted with water to obtain the cal-
ibration standards (III, IV, V).
4.4.2. LC-TOFMS
The mass analyser in studies I and III was an Ap-
plied Biosystems (Framingham, MA, USA) Mar-
iner TOF mass spectrometer, equipped with a 
PE Sciex (Concord, ON, Canada) TurboIon Spray 
source and a 10-port switching valve. The neb-
uliser gas (N2) fl ow was 0.7 l/min, the curtain gas 
(N2) fl ow was 1.2 l/min, and the heater gas (N2) 
fl ow was 8 l/min. The spray tip potential of the 
ion source was 5.5 kV, and the heater tempera-
ture was 350ºC. Spectrum acquisition time was 
2 s, and the m/z range recorded was 100-750. 
Daily instrument tuning and three-ion mass scale 
calibration was performed with 1.0 µg/ml Jef-
famine D-230 solution in acetonitrile-0.1% for-
mic acid (1+1 v/v) by infusion injection. The the-
oretical exact m/z values for the calibration ions 
were 191.17544, 249.14731, and 317.25917, 
and a minimum resolution of 5,000 was used 
in the calibration. Automated post-run internal 
mass-scale calibration of individual samples was 
performed by injecting the calibration solution in 
the beginning of each run via a 10-port switch-
ing valve equipped with a 20 µl loop. The liq-
uid chromatograph in the LC-TOFMS system was 
an Agilent Technologies (Waldbronn, Germany) 
1100 series instrument, comprising a vacuum 
degasser, autosampler, binary pump, column ov-
en and diode array detector (I, III).
In the isotopic pattern experiments (II), the 
mass analyser was a Bruker Daltonics (Bremen, 
Germany) micrOTOF mass spectrometer 
equipped with an ESI source and a 6-port di-
vert valve. The instrument was operated in posi-
tive ion mode using an m/z range of 50–800. 
The capillary voltage of the ion source was set 
at 4,500 V and capillary exit at 90 V. Nebuliser 
gas fl ow was 1.6 bar and dry gas fl ow 8 l/min. 
Drying gas temperature was set at 200ºC. Trans-
fer time of the source was 38 µs and hexapole 
RF was 75.0 Vpp. Summation of spectra was 
10000. Instrument calibration was performed 
externally prior to each sequence with sodium 
formate solution, consisting of 10 mM sodium 
hydroxide in isopropanol-0.2% formic acid (1+1, 
v/v). The theoretical exact m/z of the calibra-
tion ions were 158.9464, 240.9671, 362.9263, 
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430.9138, 498.9011 and 566.8882. Automated 
post-run internal mass-scale calibration of indi-
vidual samples was performed by injecting the 
calibrant at the beginning and at the end of each 
run via a 6-port divert valve equipped with a 100 
µl loop. Calibration was performed based on cal-
ibrant injection at the beginning of the run. The 
liquid chromatograph in the LC-TOFMS system 
was an Agilent Technologies (Waldbronn, Ger-
many) 1100 series instrument, comprising a vac-
uum degasser, autosampler, binary pump, and 
column oven. 
Chromatographic separation in both LC-
TOFMS systems was performed with a Phenom-
enex (Torrance, CA, USA) Luna C-18(2) 100 × 2 
mm (3 µm) column and a 4 × 2 mm precolumn 
in gradient mode at 40ºC. The fl ow rate was 0.3 
ml/min. The mobile phase components were 5 
mM ammonium acetate in 0.1% formic acid and 
acetonitrile. The proportion of acetonitrile was 
increased from 10% to 40% in 10 min, to 75% 
in 13.50 min, to 80% in 16 min, and held at 
80% for 5 min. Equilibrium time was 6 min and 
injection volume was 10 µl.  
4.4.3. LC-CLND
LC-CLND analysis was performed with a Hewlett-
Packard (Agilent) 1090 series liquid chromato-
graph equipped with an autosampler, three-
channel gradient pumping system, column oven 
and diode array detector. The nitrogen-specifi c 
detector was an Antek (Houston, TX, USA) 8060 
CLND. The detector was interfaced with a com-
puter using an HP (Agilent) analog to a digital 
converter. LC-CLND data were processed using 
HP Chem Station A.06.01 software (Agilent). 
For the CLND analysis, oxygen fl ow was 250 
ml/min, helium 50 ml/min and make-up helium 
50 ml/min. Ozone fl ow was 25 ml/min, and fur-
nace temperature was 1050ºC. The photo multi-
plier tube voltage was set at 750 V and the am-
plifi cation factor was 25.
External calibration in all quantitative studies 
was performed at the beginning of the data ac-
quisition sequence with caffeine standards, us-
ing calibration points at 0.75, 1.0, 1.5, 3.0, 10 
and 30 ng of nitrogen per injection. The curve fi t 
was linear with R2 >0.997.
LC separation was performed in gradient 
mode at 40ºC using a Phenomenex (Torrance, 
CA, USA) Luna C-18(2) 100 × 2 mm (3 µm) col-
umn, equipped with a 4 × 2 mm precolumn (III, 
V) and a Phenomenex (Torrance, CA, USA) Gemi-
ni C-18(2) 150 × 2 mm (3 µm) column, equipped 
with a 4 × 2 mm precolumn (IV). Mobile-phase 
components were 0.1% formic acid and metha-
nol. Diode array detector signal was recorded at 
230 nm, and peak controlled spectra were re-
corded at 210–400 nm (III, IV, V). 
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The main results of the studies are described in 
this section, more detailed results can be found 
in the original publications I-V.
5.1. Urine drug screening by LC-
TOFMS     
     
5.1.1. High-throughput screening 
based on accurate mass (I)
Gergov et al. reported a concept for urine drug 
screening by positive electrospray ionisation 
LC-TOFMS with an automated target database 
search based on molecular formulae, relying on 
the assumption that tentative identifi cation of 
drugs in urine is viable without PRS by use of 
exact monoisotopic masses and metabolite pat-
terns from the literature (Gergov et al. 2001). 
The present study evaluates this LC-TOFMS (Ap-
plied Biosystems Mariner) based screening meth-
odology to the full with a series of urine samples 
taken at autopsy and shows its scope and limi-
tations in forensic toxicology practice. The meth-
od relied on a large target database of exact mo-
noisotopic masses representing the molecular 
formulae of reference drugs and their metabo-
lites. Identifi cation by reverse search was based 
on matching sample components’ measured pa-
rameters with those in the target database, in-
cluding accurate mass and RT if available. Data 
post-processing software was developed for au-
tomated reporting of fi ndings in an easily inter-
pretable form. The screening method was vali-
dated by measuring the precision of LC RT and 
LODs for representative compounds. In addition, 
the fi ndings from autopsy urine samples were 
compared with those obtained by a GC-MS ref-
erence method.
A target database was constructed, includ-
ing 637 monoisotopic masses for the protonated 
molecules of toxicologically relevant therapeu-
tic drugs, drugs-of-abuse, metabolites, design-
er drugs and pesticides. In addition to monoiso-
topic mass, the database included the following 
data for each compound: name of compound, 
molecular formula, RT if available, and a 3-5-dig-
it compound code. The code specifi ed the com-
pound group, the number of compounds in the 
group, and the ordinal number of the compound 
in the group. The chemical and pharmacologi-
cal properties of the compounds included in the 
database varied greatly, but the majority of the 
entries represented basic drugs that could be 
obviously ionised with ESI in the positive mode. 
For 392 compounds, a PRS was available to the 
authors and the corresponding LC RT could be 
determined. The remaining database entries in-
volved mainly drug metabolites reported in the 
scientifi c literature, and for these entries, only 
the exact mass without an RT was included in 
the database. Both RT and MS ionisation data 
were recorded by running mixed reference stand-
ard solutions containing 8-10 substances each at 
a concentration of 1 µg/ml in acetonitrile-0.1% 
formic acid (1+9, v/v). Seven substances were ex-
cluded from the database, i.e. ethyl parathion, 
methyl parathion, cyclothiazide, dichlorprop, 
MCPA, ibuprofen and γ-hydroxy butyrate, be-
cause they did not ionise under the conditions 
used. Nine substances – acetazolamide, apronal-
ide, chlorpropamide, chlorthalidone, felodipine, 
phenytoin, primidone, salicylamide and sulthia-
me – had low ionisation effi ciency, and thus high 
concentrations were required to obtain suffi cient 
ion abundance.
To study the precision of RT and RRT, three 
repetitive runs were performed within one week, 
and the set of three runs was repeated two times 
at one-month intervals. Relative standard devia-
tion (RSD) values for RT and RRT were calculated 
from these nine parallel runs. For RRT calcula-
tions, dibenzepin was added to each reference 
standard solution as an internal standard. Mean 
RSD for RT and RRT was 0.50% and 0.65%, re-
spectively. Repeatability of RT and RRT proved 
to be of the same magnitude, therefore RT was 
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chosen to be the LC identifi cation parameter as 
it is simpler to manage. Recalibration of RT val-
ues was required at approximately six-month in-
tervals, mainly after changing to a new chroma-
tographic column. Although RRT use could have 
facilitated the recalibration procedure, more 
than one internal standard might have been 
needed due to the large polarity scale of the an-
alytes and the batch-to-batch variability of sorb-
ent materials.
Table 1 shows the LOD for 90 representa-
tive substances. LOD was determined by spiking 
blank urine samples with drugs and metabolites 
in decreasing concentrations, starting with an in-
itial concentration of 0.1 mg/l. If a compound 
was not detectable at 0.1 mg/l, the concentra-
tion was increased until a suffi cient response 
was obtained. Three parallel analyses were per-
formed at the LOD level, and a compound was 
considered detected if it was reported in the re-
sults report in all three cases. The criteria for re-
porting included a 30 ppm mass tolerance, a 
±0.2 min RT window and a minimum peak area 
count of 500. 
 
Compound  RT (min) LOD  
Acebutolol 7.42 0.01 
Alprenolol 10.51 0.01 
Amiodarone 16.33 10.0 
Amitriptyline 12.99 0.02 
Amphetamine 3.12 0.1 
Atenolol 1.59 0.1 
Benzoylecgonine 6.63 0.5 
Betaxolol 10.78 0.01 
Bisoprolol 9.61 0.02 
Buprenorphine 11.64 0.2 
Carbamazepine 13.12 0.02 
Carvedilol 12.36 0.1 
Celiprolol 8.88 0.02 
Chloroquine 2.94 0.2 
Chlorpromazine 13.59 0.1 
Chlorprothixene 13.81 0.5 
Cisapride 11.98 0.5 
Citalopram 11.44 0.02 
Clomipramine 13.97 0.05 
Clonazepam 14.43 0.2 
Clonidine 2.63 0.01 
Clozapine 10.73 0.05 
Cocaine 8.36 0.02 
Codeine 2.47 0.05 
Dextropropoxyphene 12.99 0.02 
Diazepam 16.04 0.01 
Diltiazem 11.74 0.02 
Dixyrazine 13.55 0.1 
Doxepin 11.51 0.02 
Ethylmorphine 5.11 0.05 
Flunitrazepam 15.04 0.05 
Fluoxetine 13.60 0.2 
Flupentixol 14.61 2.0 
Fluvoxamine 12.83 0.05 
Glibenclamide 16.80 0.01 
Glipizide 15.01 0.1 
Hydrocodone 3.94 0.1 
10-hydroxycarbamazepine 9.78 0.1 
Indomethacin 16.79 0.5 
Ketoprofen 15.44 1.0 
Levomepromazine 13.06 0.05 
Table 1. Limits of detection (LOD) and retention times (RT) for 90 com-
pounds in urine by LC-TOFMS
(mg/l)
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A mixed mode SPE sorbent combining cat-
ion exchange and hydrophobic interaction was 
chosen for extraction. A short carbon chain C4 
provided the cleanest analytical background, 
yet good recoveries. LOD in urine was ≤0.1 mg/
l for 66 of the 90 compounds studied, and only 
fi ve compounds had an LOD ≥1 mg/l. Paraceta-
mol and phenytoin were not detected even at a 
concentration of 50 mg/l, because of their low 
SPE extraction recovery and poor ionisation in 
the positive mode. For acidic compounds, neg-
ative ionisation would presumably provide low-
er LODs. However, the concentrations of acidic 
drugs in biofl uids are normally higher than those 
Lorazepam 14.29 0.2 
LSD 9.25 0.02 
Maprotiline 12.86 0.1 
MDMA (ecstasy) 4.18 0.05 
Methadone 13.11 0.01 
Metamphetamine 3.78 0.01 
Metoprolol 7.52 0.02 
Mianserine 11.12 0.02 
Midazolam 11.17 0.05 
Moclobemide 5.89 0.01 
6-monoacetylmorphine (MAM) 3.63 0.05 
Morphine 1.49 0.2 
Nicotine 1.07 0.5 
Nizatidine 1.47 0.02 
Norcitalopram 11.25 0.05 
Norclomipramine 13.78 0.1 
Nordiazepam 15.04 0.1 
Norflunitrazepam 13.81 0.2 
Normianserine 11.00 0.05 
Nortriptyline 12.77 0.05 
Olanzapine 3.29 0.05 
Orphenadrine 12.10 0.05 
Oxazepam 13.91 0.1 
Oxprenolol 9.06 0.1 
Paracetamol 2.44 >50 
Paroxetine 12.36 0.5 
Perphenazine 13.62 0.5 
Phenazone 7.32 0.05 
Phencyclidine 10.00 0.01 
Phenytoin 13.27 >50 
Pindolol 4.47 0.5 
Practolol 1.91 0.05 
Promazine 12.17 0.1 
Propranolol 10.35 0.01 
Quinine 7.36 0.1 
Ranitidine 1.73 0.05 
Risperidone 9.63 0.02 
Selegiline 6.27 0.1 
Sotalol 1.69 0.5 
Sulpiride 1.96 0.01 
Thioridazine 14.51 0.5 
Timolol 7.11 0.02 
Tramadol 7.45 0.01 
Trimipramine 13.25 0.1 
Venlafaxine 9.42 0.01 
Verapamil 13.03 0.02 
Warfarin 16.13 0.02 
Zolpidem 9.02 0.01 
Zopiclone 7.34 0.2 
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of basic drugs (Baselt 2004), and consequent-
ly, the present method also allows detection of 
many acidic drugs. Generally, the LODs obtained 
with the present method were higher than those 
reported with MRM target analyses by LC-MS 
(Van Bocxlaer et al. 2000), but at the same level 
as in other screening applications (Gergov et al. 
2000, Thevis et al. 2001).
Fifty authentic autopsy urine samples were 
analysed by the LC-TOFMS method, and the re-
sults were compared with a reference GC-MS 
method applying comprehensive commercial 
spectrum libraries. Figures 5a and 5b show an 
LC-TOFMS total ion chromatogram (TIC) and a 
corresponding results report list for an autopsy 
urine sample. Compounds marked bold in Fig-
ure 5b are considered as true positive fi ndings 
in the report. The number of true positives, false 
positives, false negatives and unidentifi ed com-
pounds (not included in the database) by LC-
TOFMS are shown in Figure 6. For compounds 
with an RT available, this classifi cation was based 
on the following criteria. Entries in the report 
with molecular mass of ≥200 Da and mass error 
≤20 ppm were considered true positive fi ndings 
if a parent drug and at least one metabolite were 
reported. For entries with molecular mass <200 
Da, the mass error tolerance was 30 ppm. En-
tries were considered as false positive fi ndings, if 
the mass criteria were met but without metabo-
lites being reported and with a negative GC-MS 
screen. The total number of compounds identi-
fi ed by LC-TOFMS was higher than by GC-MS. 
However,  some acidic  compounds,  such as ibu
profen and valproic acid, were not detected by 
LC-TOFMS as they were not ionisable in positive 
ESI, and therefore they were not included in the 
database. Seven caffeine fi ndings were missed 
by LC-TOFMS, mainly due to the low mass and 
poor peak shape of caffeine, resulting in a mass 
error higher than 30 ppm. The false positive fi nd-
ings, such as meclozine, amitriptyline and dex-
tropropoxyphene, were apparently endogenous 
components from autopsy urine samples with 
unresolved adjacent molecular mass.
Figure 5a. A total ion chromatogram of a solid-phase extracted autopsy urine sample acquired by 
LC-TOFMS.
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Sample ID: 4551 Mass List Used: C:\Mariner\Program\screening\TOFseu070307.xls
Acquisition Date: Sep 02 02:02:00 2008 Set File Used: C:\Mariner\Program\screening\APScreen.set





[min] Err [ppm] Err [mDa] Peak Area Mass Found Ref. Mass Formula Reg. No.
NORDIAZEPAM 15,08 15,16 -0,08 -9,6 -2,6 2349,4 271,0659 271,0633 C15H11N2OCl 154
OXAZEPAM 14,05 14,01 0,04 -8,2 -2,3 5041,9 287,0605 287,0582 C15H11N2O2Cl 155
DIAZEPAM 16,07 16,17 -0,1 -12,6 -3,6 908,4 285,0825 285,0789 C16H13N2OCl 1341
TEMAZEPAM 15,18 15,31 -0,13 -4,6 -1,4 11083,5 301,0752 301,0738 C16H13N2O2Cl 1343
CAFFEINE 4,22 4,2 0,02 -17,1 -3,3 4316,5 195,091 195,0877 C8H10N4O2 1451
CODEINE 2,37 2,29 0,09 -3,4 -1 16648,6 300,1604 300,1594 C18H21NO3 1831
NORCODEINE 2,16 2,06 0,11 -19,1 -5,5 562,2 286,1492 286,1438 C17NH19O3 1832
4-HYDROXYPROPRANOLOL 12,63 0 12,63 -12,7 -3,5 1318,2 276,1629 276,1594 C16H21NO3 2144
NORHYDROCODONE 2,16 0 2,16 -19,1 -5,5 562,2 286,1492 286,1438 C17H19NO3 2932
HYDROXYCLOMIPRAMINE 11,03 0 11,03 -0,9 -0,3 633,1 331,1575 331,1572 C19H23N2OCl 3633
NORCLOBAZAM 14,05 0 14,05 -8,2 -2,3 5041,9 287,0605 287,0582 C15N2H11O2Cl 3832
P-HYDROXYNOREPHEDRINE 1,31 0 1,31 21,3 3,6 973,3 168,0983 168,1019 C9H13NO2 3933
NORALPRENOLOL 4,08 0 4,08 -17 -4 2127,2 236,1685 236,1645 C14H21NO2 7633
P-HYDROXYPHENYTOIN 14,86 0 14,86 25,7 6,9 2029,7 269,0852 269,0921 C15H12N2O3 7942
M-HYDROXYPHENYTOIN 14,86 0 14,86 25,7 6,9 2029,7 269,0852 269,0921 C15H12N2O3 7943
3,4-DIHYDRODIHYDROXYPHENYTOIN 12,95 0 12,95 -5,8 -1,7 1002,5 287,1043 287,1026 C15H14N2O4 7944
TRAMADOL 7,41 7,37 0,04 5,1 1,3 52180 264,1945 264,1958 C16NH25O2 8861
O-DESMETHYLTRAMADOL 3,72 3,56 0,16 -3,7 -0,9 6501,2 250,1811 250,1802 C15H23NO2 8862
NORTRAMADOL 7,59 7,48 0,11 -19,3 -4,8 2236 250,185 250,1802 C15H23NO2 8863
O-DESMETHYLNORTRAMADOL 4,08 3,88 0,2 -17 -4 2127,2 236,1685 236,1645 C14H21NO2 8864
NORMEDAZEPAM 11,7 0 11,7 -21,4 -5,5 795,5 257,0895 257,084 C15H13N2Cl 9466
HYDROXYMETHYLTOLBUTAMIDE 16,07 0 16,07 28 8 1772,3 285,0824 285,0904 C12H16N2O4S 9533
DINORVENLAFAXINE 3,72 0 3,72 -3,7 -0,9 6501,2 250,1811 250,1802 C15H23NO2 9844
DINORVENLAFAXINE 7,59 0 7,59 -19,3 -4,8 2236 250,185 250,1802 C15H23NO2 9844
NORATROPINE 12,63 0 12,63 -12,7 -3,5 1318,2 276,1629 276,1594 C16H21NO3 10432
ZOLPIDEM 8,94 8,92 0,02 0,4 0,1 7891,4 308,1756 308,1757 C19H21N3O 10941
2-QUINIDONE 3,4 0 3,4 -15,7 -5,4 1409,4 341,1913 341,186 C20H24N2O3 12132
3-HYDROXYQUINIDINE 3,4 0 3,4 -15,7 -5,4 1409,4 341,1913 341,186 C20H24N2O3 12133
QUININE 7,2 7,17 0,03 -8,8 -2,8 7547 325,1939 325,1911 C20N2H24O2 12231
3-HYDROXYQUININE 3,4 0 3,4 -15,7 -5,4 1409,4 341,1913 341,186 C20H24N2O3 12232
2-HYDROXYQUININE 3,4 0 3,4 -15,7 -5,4 1409,4 341,1913 341,186 C20H24N2O3 12233
NORPROPAFENONE 2,37 0 2,37 -3,4 -1 16648,6 300,1604 300,1594 C18H21NO3 12933
INDOMETHACIN 16,85 16,93 -0,08 5,1 1,8 785,4 358,0822 358,0841 C19NH16O4Cl 13231
HALOPERIDOL REDUCED 15,72 0 15,72 6,3 2,4 4908,6 378,1607 378,1631 C21H25NO2ClF 13654
DINORACETYLMETHADOL 7,23 0 7,23 28,1 9,2 1260 326,2023 326,2115 C21H27NO2 15243
3-METHYLNORFENTANYL 1,38 0 1,38 -10,2 -2,5 6546,6 247,183 247,1805 C15H22N2O 15522
METHOXYTADALAFIL 16,25 0 16,25 26,1 10,2 1107,9 392,1502 392,1605 C22H21N3O4 16433
RIVASATIGMINE METAB2 11,03 0 11,03 -22,4 -3,7 882,1 164,1107 164,107 C10H13NO 17033
NORDIHYDROCODEINE 14,79 0 14,79 -4,2 -1,2 10135,7 288,1606 288,1594 C17H21NO3 17222
NORSIBUTRAMINE 8,94 0 8,94 12 3,2 705,1 266,1638 266,167 C16H24ClN 17432
2C-O-4 11,81 0 11,81 -22,8 -5,5 558,1 240,1649 240,1594 C13H21O3N n/a
IP 11,81 0 11,81 -22,8 -5,5 558,1 240,1649 240,1594 C13NH21O3 n/a
EMM 11,81 0 11,81 -22,8 -5,5 558,1 240,1649 240,1594 C13H21O3N n/a
MEM 11,81 0 11,81 -22,8 -5,5 558,1 240,1649 240,1594 C13NH21O3 n/a
DIBENZEPIN 9,4 9,31 0,09 -14,7 -4,4 4058,2 296,1801 296,1757 C18H21N3O n/a
BISOPROLOL 9,54 9,52 0,02 -6,1 -2 44628,6 326,2346 326,2326 C18NH31O4 n/a
AJMALINE 8,01 0 8,01 -0,1 0 565,4 327,2067 327,2067 C20H26N2O2 n/a
AJMALINE 9,54 0 9,54 -0,1 0 2509 327,2067 327,2067 C20H26N2O2 n/a
MECLOZINE 15,72 15,56 0,16 22,4 8,8 2069,9 391,1848 391,1936 C25H27N2Cl n/a
Figure 5b. A results report list generated by the analysis macro program for the autopsy urine 
sample of Figure 5a. Entries in bold are considered true positive fi ndings.
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Identifi cation based solely on accurate mass 
at the present level of mass accuracy was consid-
ered insuffi ciently reliable, allowing only tenta-
tive identifi cation of metabolites without a PRS. 
However, the combination of accurate mass, me-
tabolite pattern, and available RTs proved to be 
feasible. The LC-TOFMS method described has 
been in daily routine use for four years, and all 
parts of the procedure, from sample preparation 
to data analysis, have complied with the high-
throughput screening concept.
5.1.2. The effect of isotopic pattern 
in screening analysis (II)  
     
The effect of isotopic pattern determination in 
combination with accurate mass was evaluated 
for identifi cation in LC-TOFMS screening. The 
principle of the LC-TOFMS method was similar 
to that described in the previous study (I), but a 
new generation TOFMS analyser (Bruker micrO-
TOF) with improved performance was used. The 
instrument allowed measuring a numerical value 
for the isotopic pattern match, SigmaFitTM, as a 
new identifi cation parameter together with the 
accurate mass on a routine basis. Two identifi ca-




Correct findings by LC-TOFMS
False positives by LC-TOFMS
False negatives by LC-TOFMS
Unidentified by LC-TOFMS
Figure 6. Compounds detected by LC-TOFMS and compared by GC-MS from 50 successive autopsy 
urine samples. Unidentifi ed compounds are those not included in the LC-TOFMS database.
sentative autopsy urine samples: combination of 
accurate mass and isotopic pattern, and accurate 
mass only. The number of entries in the result re-
port list and the proportion of true positive fi nd-
ings were studied.
The database was based on that used in 
study I, but it was extended to include 735 en-
tries. From the data acquired by LC-TOFMS, the 
automated database search reported hits with-
in a selected retention time window, peak ar-
ea, mass tolerance and isotopic pattern match. 
A post-processing script created extracted ion 
chromatograms (EIC) of the expected MH+ ions 
for each compound of the database within a 
very narrow m/z window (±3×10
-3
). On these, 
trace peak detection was applied, and a MS 
spectrum was created for each chromatographic 
peak. Each MS spectrum was associated with a 
distinct substance in the database and a Sigma-
Fit (isotopic pattern match) was calculated. This 
included generation of a theoretical isotope pat-
tern and calculation of a match factor based on 
the deviation from the measured ion abundanc-
es. Final sorting and scoring of the result list was 
performed by an MS Excel script based on RT, 
mass error tolerance, SigmaFit and peak area. 
An example of measured and calculated isotopic 
patterns is shown in Figures 7a and 7b.
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Five parallel runs of each solid-phase-extract-
ed autopsy urine samples were performed by LC-
TOFMS. For data handling, two data processing 
software settings were used. In the fi rst proce-
dure (procedure A), identifi cation was based on 
both accurate mass and isotopic pattern, with a 
SigmaFit upper limit set at 0.03 and a mass error 
tolerance set at 10 ppm. In the second procedure 
(procedure B), identifi cation was based on accu-
rate mass only, with a SigmaFit upper limit set at 
1.0 and a mass error tolerance set at 10 ppm. 
In both procedures, the minimum area count 
was set at 50,000 and a retention time window 
of ±0.3 min was used for those compounds for 
which retention time was available in the data-
base. The entries in the results report lists by pro-
cedure A and procedure B were compared, and 
the fi ndings were classifi ed as true positive, false 
positive and false negative fi ndings. The refer-
ence list of true positive fi ndings was based on 
the laboratory’s established methods of investi-
gation and case background information. 
The mean SigmaFit value for the true posi-
tive fi ndings was 0.0066 (median 0.0051). The 
selected SigmaFit tolerance value of 0.03 was 
exceeded by only one true positive entry, repre-
senting hydroxyalprazolam. This was a false neg-
ative by procedure A. In this case the SigmaFit 
value was as high as 0.5 in all fi ve parallel runs 
because of a co-eluting matrix compound with 
an adjacent molecular mass. The mean of the 
mass error absolute values was 2.51 ppm (medi-
an 2.17 ppm), corresponding to 0.65 mDa (me-
dian 0.60 mDa), and the range was from -4.90 
to 9.80 ppm. The mass accuracy or SigmaFit was 
not affected by ion abundance or the concentra-
tions of the detected compounds. 
TIC and EIC for a urine sample are shown in 
Figures 8a and 8b, respectively, and the corre-
sponding results report list is presented in Figure 
8c. The compounds highlighted by the software 
are those for which RT, SigmaFit and mass er-
ror were within the pre-selected limits. The com-
pound codes facilitated the interpretation of the 
fi ndings by connecting parent compounds with 
their metabolites (see Materials and Methods).
The lengths of the results report lists by pro-
cedure A and procedure B are compared in Fig-
ures 9a and 9b. The false positive entries were 
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RT was not available in the database due to a 
lack of reference substances. The number of 
false positives and the capability of detecting 
substances at trace levels is a compromise, and 
in practical work, it is important to optimise the 
sensitivity of the LC-TOFMS method. Procedure 
A, based on accurate mass and isotopic pattern, 
produced 61% true positive fi ndings. Procedure 
B, based on accurate mass only, produced more 
false positive fi ndings and the proportion of true 
positive fi ndings was 49%. The false negative 
fi ndings in procedure A represented hydroxy-
alprazolam (see above) and dibenzepin in both 
procedures. The latter was due to a co-eluting 
doxepin N-oxide peak, possessing an molecular 
mass adjacent to dibenzepin. 
A mass tolerance of 10 ppm and a Sigma-
Fit upper limit of 0.03 proved to be appropriate 
values for identifi cation. Isotopic pattern match 
clearly decreased the number of false positive 
entries on the result report lists. This was ob-
served especially with concentrated and putre-
fi ed urines, but also with relatively clean sam-
ples. Very constant SigmaFit and mass error val-
ues were obtained for true positive fi ndings. The 
present LC-TOFMS method allowed the use of 
a narrower mass window than in the original 
method (I), in which a mean mass error was 7 
ppm and a mass tolerance of 30 ppm was used.







Figure 9a ja 9b. Lengths of the results report lists by LC-TOFMS using 
procedure A, utilising SigmaFit and accurate mass (a), versus pro-
cedure B, utilising accurate mass only (b). The false positive entries 
were mainly metabolites for which retention time was not available 
in the database.










Isotopic pattern determination is not a new 
invention; it has been previously used in sub-
stance identifi cation already in 1980s by using 
low resolution MS (Kavanagh 1980). Isotopic 
pattern has proven useful for confi rming com-
pound identity and facilitating chemical structure 
characterisation by mass spectrometry, because 
it is information-rich and almost independent of 
instrument type and ionisation technique (Rock-
wood et al. 2003). The present thesis is the fi rst 
to utilise isotopic pattern determination in com-
prehensive LC-TOFMS screening analyses based 
on a target database search. Use of isotopic pat-
terns clearly improved the performance of the 
method, but false positives report entries were 
still produced for compounds for which PRS were 
not available. Hence, the combination of accu-
rate mass and isotopic pattern provides a meth-
od for tentative identifi cation, which should then 
be confi rmed with other methods.
5.2. Analysis of street drugs (III)
Twenty-one seized street drug samples were ana-
lysed qualitatively by LC-TOFMS (Mariner), using 
the method described earlier (I), and quantifi ed 
by LC-CLND using caffeine as single secondary 
standard. The sample preparation procedure was 
kept simple and rapid, comprising only dilution. 
The results were compared with those obtained 
by accredited reference methods (see original 
publication). The LC-TOFMS database consisted 
of 735 compounds, including therapeutic drugs, 
drugs-of-abuse, metabolites and designer drugs. 
Identifi cation of designer drugs was based on ac-
curate mass only, because the corresponding PRS 
were not available. Table 2 shows the results ob-
tained by LC-TOFMS and LC-CLND, compared 
with those of the reference methods.
The logo of the Department of Forensic Medicine 
designed by Professor Kari Suomalainen.
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Identifi cation of the active compounds in the 
street drug samples was straightforward since 
the number of drug-like components in the sam-
ples varied only from one to fi ve, and the sam-
ple matrix was relatively simple compared to the 
biological material. An example TIC is shown in 
Figure 10. The LC-TOFMS results report listed on-
ly one entry per detected mass, except for sam-
ple 16, in which two entries of identical molec-
ular formula were listed. Based on the accurate 
mass of the protonated molecule, identical mo-
lecular formulae cannot be differentiated, and 
additional techniques should be used for identi-
fi cation. In sample 9, the reference method was 
not able to identify benzoylecgonine and ecgo-
nine methyl ester, but these entries were obvi-
ously true positive fi ndings as by-products of co-
caine. The additional compounds found by the 
reference methods, such as desethyl chloroquine 
(sample 1), acetylcodeine (samples 1 and 11), pi-
racetam (sample 4) and cinnamoylcocaine (sam-
ple 4), were not included in the LC-TOFMS da-
tabase. In sample 14, a trace of 2,4,5-trimeth-
oxyphenethylamine was detected by LC-TOFMS 
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6 5-methoxytryptamine 1.2 5-methoxytryptamine 97 0.12   
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7.2   
17 amphetamine -9.2 amphetamine 38 0.34 41 -7.3 
18 amphetamine -8.7 amphetamine 27 4.5 25 8.0 
19 amphetamine -15.6 amphetamine 11 7.5 14 -21 
20 amphetamine -11.3 amphetamine 33 4.1 28 18 
21 amphetamine -12.9 amphetamine 17 7.4 18 -5.6 
a Mixture of two samples 
b Not included in LC-TOFMS mass library 
c NR, not reported 
Table 2. Identifi cation of seized samples by LC-TOFMS and quantifi cation by LC-CLND
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and interpreted as a true positive fi nding, since 
the compound was structurally related to the 
main fi nding of 2,5-dimethoxyphenethylamine. 
In sample 16, the small peak of 5,6-dimethoxy-
N-isopropyl-N-methyltryptamine was considered 
a false positive fi nding. The mean and median of 
the absolute values of the mass errors between 
calculated and measured mass were 7.2 and 
5.9 ppm, respectively, but for one low-molecu-
lar-weight amphetamine, the mass error ranged 
from 3.2 to even 24 ppm.
The identifi ed components were quantifi ed 
using the single-calibrant LC-CLND method. 
Three parallel analyses in three dilutions were 
performed, and the concentration was calcu-
lated from the dilution, in which the peak area 
was within the range of the caffeine calibration 
standards. The amount of nitrogen per injected 
sample component was calculated directly from 
the caffeine response curve, and the drug con-
centrations were calculated using the ratio of ni-
trogen content and molecular mass of the com-
pound. An example LC-CLND chromatogram of 
a seized sample is shown in Figure 11. Quantita-
tive results by reference methods were available 
for 11 sample components of the 32 identifi ed 
compounds. The mean relative difference be-
tween the results by LC-CLND and the reference 
methods was 11%, and the range was 4.2-21%. 
A mean RSD of 6% was obtained for three paral-
lel LC-CLND analyses. In sample 5, the amount of 
5-methoxy-N,N-dimethyltryptamine was as high 
as 120%, possibly because of co-elution with a 
matrix component. This co-elution was not de-
tected by LC-TOFMS, but the UV chromatogram 
indicated a fronting peak with a UV spectrum 
identical to the main peak. 


































Figure 10. LC-TOFMS total ion chromatogram of a seized street drug sample, obtained after a sim-
ple dilution
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The present approach combining LC-TOFMS 
and LC-CLND was an extremely quick and 
straightforward way of analysing drugs in seized 
material. The sample compounds were identifi ed 
properly by accurate mass measurement, provid-
ed that the corresponding entries were included 
in the database. The same precautions concern-
ing identifi cation apply here as mentioned in the 
previous studies (I, II). LC-CLND is an effectual 
tool for the quantifi cation of substances in pow-
dered samples, which generally do not require 
advance extraction and purifi cation. Criminalis-
tics laboratories would evidently increase their 
throughput by using fewer and more effi cient 
methods, such as the present two, instead of ap-
plying a range of dedicated target methods. 
5.3. Quantification of drugs in 
blood by LC-CLND
5.3.1. Basic lipophilic drugs (IV)
Quantifi cation of basic lipophilic drugs in blood 
specimens was studied by LC-CLND, based on 
the detector’s equimolar response to nitrogen, 
and by using caffeine as a single secondary 
standard. Because of the complexity of the bio-
logical matrix, an extraction procedure was ap-
plied prior to chromatography. Analysis without 
PRS necessitated the estimation of the mean re-
covery of extraction for basic lipophilic drugs in 
plasma and whole blood by using representa-
tive model compounds. The validity of the estab-
lished mean extraction recoveries was verifi ed by 
analysing six profi ciency test samples by the sin-
gle-calibrant LC-CLND method.
LLE recoveries with butyl chloride-isopro-
pyl alcohol for basic lipophilic drugs were de-
termined from blood specimens spiked with the 
respective reference standards. The study was 
carried out with 33 drugs, representing antide-
pressants, antihistamines, antipsychotics, cardio-
vascular drugs and opioids (Table 3). The drug 
was considered basic and lipophilic if the com-
pound’s calculated log D value (octanol/water) 
at the extraction pH of 11 was greater than 1.5 
and an aliphatic amino group was present in the 
molecule. Amphoteric drugs were not analysed 
in the study, except for pentazocine, which, de-
spite containing a phenolic hydroxyl group, is 
suffi ciently lipophilic to be extracted outside of 
the optimal pH. The recoveries were determined 
at two concentrations, 0.2 and 1.0 mg/l, repre-
senting therapeutic and toxic levels, respective-
ly. Particularly low dose-drugs were not includ-
ed in the study. The recoveries were determined 
by LC-CLND in four parallel analyses spiked with 
the PRS in a regular manner. The mean extrac-
tion recoveries in plasma at 0.2 mg/l and 1.0 mg/
















































Figure 11. LC-CLND chromatogram for the sample of Figure 10, obtained after a simple dilution
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l levels were 88 ± 16 and 92 ± 16%, respective-
ly, and in whole blood 80 ± 17 and 87 ± 16%, 
respectively. The grand mean extraction recover-
ies based on concentrations in both plasma and 
whole blood were 90 ± 18 and 84 ± 16%, re-
spectively. The RSD of four parallel injections was 
below 15%.
 
Compound Log D Recovery of extraction 
  Plasma Whole blood 
  0.2 mg/l RSD 
(%) 
1.0 mg/l RSD 
(%) 
0.2 mg/l RSD 
(%) 
1.0 mg/l RSD 
(%) 
Amitriptyline 4.91 78 3 79 8 84 5 66 9 
Aripiprazol 5.59 87 4 100 3 68 6 61 14 
Bisoprolol 2.13  -  -  -  - 89 11 95 2 
Chlorpromazine 5.19 51 12 107 2 103 5 98 2 
Citalopram 2.50 102 7 87 11 97 4 85 4 
Clomipramine 5.51 96 2 95 3 62 4 94 7 
Clozapine 3.48 96 4 80 5 85 4 72 10 
Desipramine 4.04 98 6 95 5 75 10 81 8 
Dibenzepin 1.76 57 5 99 6 70 3 82 10 
Diphenhydramine 3.66 98 3 97 2 68 4 98 1 
Fluoxetine 4.04 64 9 118 5 71 2 86 14 
Fluvoxamine 3.10 108 3 58 10 116 11 111 6 
Imipramine 4.79 90 2 116 1 82 4 99 10 
Levomepromazine 4.93 89 3 96 3 42 10 38 14 
Methadone 4.19 99 2 98 3 88 9 86 11 
Metoprolol 1.78 86 14 69 8 88 9 98 2 
Mianserine 3.67 68 1 85 9 72 11 61 10 
Mirtazapine 2.75    -  - 68 8 72 9 
Norcitalopram 3.13 92 6 98 2 105 5 112 3 
Norclomipramine 4.77 97 5 96 5 74 10 88 9 
Normethadone 2.76 88 2 101 2 97 2 95 7 
Nortramadol 1.88 98 2 91 3 99 3 102 1 
Nortrimipramine 4.38 99 5 102 4 72 9 99 3 
Nortriptyline 5.61 109 5 82 5 89 4 92 7 
Pentazocine 3.58  -  -  -  - 76 4 68 9 
Promazine 4.62 66 5 72 7 47 5 78 7 
Propranolol 3.09 96 4 93 6 98 9 98 8 
Quetiapine 1.57 96 2 97 4 70 12 104 4 
Thioridazine 6.11 57 9 47 11 63 6 84 11 
Tramadol 2.49 101 5 94 8 93 9 109 2 
Trimipramine 5.14 85 3 121 5 68 4 73 17 
Venlafaxine 2.90  -  -  -  - 95 5 94 1 
Verapamil 3.89 110 3 99 3 65 5 93 4 
Mean  88 5 92 5 80 6 87 7 
Median  94 4 96 5 76 5 92 7 
Table 3. Liquid-liquid extraction (LLE) recoveries with butyl chloride-isopropyl alcohol for 
basic lipophilic drugs from blood specimens.
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The validity of the single-calibrant LC-CLND 
method was studied by analysing profi ciency 
test samples, without PRS, using the universal 
extraction recoveries established (90% for plas-
ma and 84% for whole blood) (Figure 12a and 
12b). Based on eight determinations in plasma 
and 12 in whole blood samples, the mean ac-
curacy in plasma and whole blood was 24 and 
17%, respectively. The maximum error was 31% 
for both specimens. Repeatability was studied by 
performing four parallel analyses: the RSD for 
plasma and whole blood was 19 and 17%, re-
spectively. The standard score (z-score) indicates 
how many standard deviations an observation is 
above or below the mean, allowing comparison 
of observations from different normal distribu-
tions. Based on the profi ciency test results, the 
z-score of the single-calibrant LC-CLND method 
was better than one (excellent) in plasma for two 
out of eight substances and in whole blood for 
nine out of 12 substances. The z-score was bet-




































































The butyl chloride-isopropyl alcohol extrac-
tion method yielded relatively clean extracts, re-
sulting in low background noise in the LC-CLND 
chromatograms (Figure 13). Butyl chloride was 
chosen as an extraction solvent based on its 
proven applicability to basic lipophilic drugs in 
analytical toxicology. Recognised already in the 
1970s (Siek 1978), butyl chloride has been found 
to provide clean and effi cient extraction with a 
list of recoveries from an aqueous buffer at pH 9 
(Demme 2003) reported for over 200 toxicologi-
cally relevant substances. Isopropyl alcohol was 
added to the extraction solvent to improve the 
recovery of polar compounds. Emulsion forma-
tion was observed in individual cases, especial-
ly with plasma samples, and the phenomenon 
was found to signifi cantly affect the recoveries 
of the late-eluting, mostly lipophilic compounds. 
In cases where visible emulsion formation was 
observed, the sample preparation was repeated. 
For reducing emulsion formation, samples were 



































































































































































































Figure 12a ja 12b. LC-CLND results obtained without primary reference standards for plasma (a) 
and whole blood (b) profi ciency test samples. Error bars for the reference values represent 95% 
confi dence limits.
Figure 13. LC-CLND chromatogram for a whole blood profi ciency test sample after liquid-liquid 




Effi cient LC separation plays a key role in LC-
CLND analysis. The chromatographic separation 
was developed for basic lipophilic compounds, 
without optimising the resolution for any par-
ticular set of compounds. As the mobile phase 
must be volatile and free of nitrogen, the reper-
toire of suitable buffers was limited, and metha-
nol was used instead of acetonitrile. Overall, the 
study was limited to drugs for which no co-elut-
ing compounds from the matrix were detected, 
and hence clomipramine and norclomipramine, 
for example, were excluded from the plasma 
analyses.
The present study was the fi rst to apply LLE 
in a single-calibrant LC-CLND analysis. The re-
peatability of the LLE method was found to be 
suffi ciently constant for forensic and clinical toxi-
cology purposes. In the methods published earli-
er, protein precipitation has been used in sample 
preparation (Deng et al. 2004). However, during 
the development of the present method, both 
protein precipitation and the SPE approach pro-
duced unsatisfactory results, even when using 
automatic sample preparation. LC-CLND func-
tioned well with LLE-treated biological samples, 
and even after thousands of injections, no major 
maintenance operations were needed.
5.3.2. Tramadol and metabolites (V)
The opioid analgesic drug tramadol was taken as 
an example of the use of the single-calibrant LC-
CLND method in a clinical context. After a sin-
gle dose of 100 mg tramadol to four volunteers, 
tramadol and its two main metabolites, O-des-
methyltramadol and nortramadol, were quan-
tifi ed from plasma samples without PRS by LC-
CLND, applying the extraction recoveries ob-
tained with model compounds. The study was 
applied to a pharmacogenetic setting by deter-
mining the tramadol metabolite ratios and the 
CYP2D6 genotypes for each study subject.
The extraction recoveries were determined 
for the three analytes (tramadol, O-desmethyl-
tramadol, and nortramadol) for the two model 
compounds for extraction (venlafaxine and ke-
tobemidone) and for the internal control (dextro-
propoxyphene) in four parallel analyses of plas-
ma spiked at concentrations of 0.05, 0.15 and 
0.50 mg/l. The structures of the compounds and 
their log D values (octanol/water) at different pH 
values are shown in Figure 14a and b. The model 
compounds with chemical properties similar to 
tramadol and its metabolites were used for es-
tablishing the extraction recoveries from plasma. 
Venlafaxine, as a basic compound possessing a 
tertiary aliphatic amine group, represented tra-
madol and nortramadol. Ketobemidone with a 
tertiary aliphatic amine group and a phenolic hy-
droxyl group is amphoteric and represented O-
desmethyltramadol. Dextropropoxyphene was 
used as an internal control to monitor the qual-
ity of sample preparation and chromatography; 
however, it was not used to correct the results. 
The standard deviation (SD) of day-to-day reten-
tion times over a three-week period was below 
0.03 min. High caffeine concentrations were 
found to interfere with nortramadol under the 
present chromatographic conditions, and conse-
quently the study subjects were advised to re-
frain from consuming caffeine for two days be-
fore sampling. The LOQ for tramadol, nortrama-
dol and O-desmethyltramadol was 15, 15 and 
30 µg/l, respectively. These limits were suffi cient-
ly low for analysing the compounds at therapeu-
tic concentrations, although the required plasma 
sample volume was as high as 5 ml. The LOQs 
obtained were at the same level as those report-
ed for GC-MS (Goeringer et al. 1997), but not as 
low as with LC coupled to fl uorescence detec-
tion (Rouini et al. 2006).
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The mean extraction recoveries for tramadol, 
nortramadol and O-desmethyltramadol were 
88%, 95% and 32%, respectively, with an RSD 
between 11 and 14%. The mean extraction re-
coveries for the model compounds, venlafaxine 
and ketobemidone, were 89% and 30%, re-
spectively. The single-calibrant LC-CLND analysis 
of the study subjects’ plasma samples included 
the following procedure: the recovery of venla-
faxine (89%) was used for correcting tramadol 
and nortramadol analysis, and the recovery of 
ketobemidone (30%) was used for correcting 
O-desmethyltramadol analysis. The LC-CLND re-
sults were compared with those obtained by a 
GC-MS reference method (Figure 15). The mean 
difference between the results of the two meth-
ods for tramadol, nortramadol and O-desmeth-
yltramadol was 8%, 32% and 19%, respectively, 
and the range was 0-60%. These values repre-





























































Figure 14. Structures and predicted log D values at different pH using ACDLabs 8.0 software: Ba-
sic analytes, tramadol and nortramadol, and their model compound venlafaxine (a); Amphoteric 
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Figure 15. The number of functional CYP2D6 genes and the corresponding metabolite ratios 
measured by LC-CLND and GC-MS.
the mean values are similar to or only slightly 
higher than the bioanalytical within-method vali-
dation criteria of 15-20% for accuracy and preci-
sion (Shah et al. 2000b). Despite of the relatively 
high differences between LC-CLND and GC-MS 
results, the magnitude of the results was similar.
The cytochrome P450 (CYP) isoenzyme CYP2D6 
has been shown to convert tramadol to O-des-
methyltramadol, while CYP3A4 is believed to 
convert tramadol to nortramadol (Paar 1992). 
CYP2D6 is generally polymorphic, and it has im-
plications for tramadol/O-desmethyltramadol ra-
tios. Figure 15 shows the number of functional 
CYP2D6 genes of each of the four study sub-
jects. Subject 1 had an ultrarapid metaboliser 
phenotype with active whole gene duplication, 
and subjects 2-4 had an extensive metaboliser 
phenotype with one or two functional genes. A 
correlation between the number of functional 
genes and the tramadol/O-desmethyltramadol 
plasma metabolite ratios was found in the study, 
despite the small subject pool. The metabolic ra-
tios obtained for extensive metabolisers were, ir-
respective of technique, comparable to the range 
reported earlier (Borlak et al. 2003). The present 
study shows that single-calibrant LC-CLND can 
be used to provide metabolic ratios of tramadol 
and other substances within therapeutic drug 
monitoring and toxicology, if model compounds 
are used to establish the extraction recoveries. A 
disadvantage with biological samples is the lim-
ited sensitivity of the detector, for which a 5 ml 
sample volume was required.
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6. GENERAL DISCUSSION
The following three dimensions can be associ-
ated with the quality of the outcome of foren-
sic and clinical drug analysis: 1) qualitative anal-
ysis should cover a wide spectrum of toxic and 
abused substances with a high degree of relia-
bility, 2) quantitative analysis should measure the 
quantity of the relevant substances with reason-
able accuracy, e.g. differentiating therapeutic, 
toxic and lethal concentrations, and 3) the anal-
ysis should be completed within an acceptable 
period of time. Unequivocal determination of the 
identity of compounds is of crucial importance in 
forensic science and toxicology because of legal 
consequences, and failure in analysis may lead 
to overturning of court convictions and a loss of 
confi dence in the laboratory (Hibbert 2003). In a 
clinical context, incorrect analysis may result in a 
misdiagnosis and costly unnecessary treatment, 
or worse, in the lack of necessary treatment.
There is no general agreement on how a suf-
fi cient level of certainty should be achieved in 
the qualitative bioanalysis of drugs. In his polem-
ical review, de Zeeuw concluded that substance 
identifi cation is a neglected and misunderstood 
domain in analytical toxicology and suggested 
rapid and concerted actions to improve gener-
al knowledge, to defi ne uniform strategies in 
the analytical approach and in the interpreta-
tion of results, and to set up and maintain suit-
able banks of reference substances and compu-
terised databases to allow unambiguous identi-
fi cation (de Zeeuw 2004). The information pow-
er of different analytical techniques has, in fact, 
been discussed (Hartstra et al. 2000) using sev-
eral mathematical approaches, such as mean 
list length method, discriminating power (Mof-
fat et al. 1978) and information content (Mas-
sart 1973). But these theoretical considerations, 
though valuable in themselves, give little practi-
cal advice for judging the validity of a particular 
result in a particular case. An extensively cited 
review by Rivier (Rivier 2003) is more practical-
ly oriented and brings together detailed guide-
lines and requirements for chromatographic and 
spectrometric techniques from different organi-
sations, including WADA, the International As-
sociation of Forensic Toxicologists, the Centre for 
Veterinary Medicine of the US Food and Drug 
Administration, and the European Union (EU). 
Very detailed rules are presented in EU Commis-
sion Decision 2002/657/EC implementing Coun-
cil Directive 96/23/EC, concerning performance 
of analytical methods and the interpretation of 
results for laboratories involved in animal and 
meat residues analyses (European Union 2002). 
For instance, MS techniques measuring specifi c 
ions were valuated according to the number of 
information points (IP) related to the technique. 
Interestingly, LC-MS was given an IP of 1.0 for 
an ion (or a precursor ion) and 1.5 for a prod-
uct ion, but for high resolution LC-MS, these 
values were 2.0 and 2.5, respectively. The RRT 
criteria for LC were <2.5%. To attain the mini-
mum requirement of 4.0 IPs, at least two low-
resolution MRM ion transitions are required or 
one at high resolution. A proposal to specify and 
change these rules has been recently published, 
stating that at least three TOFMS ions would be 
required versus four low-resolution MS ions in 
order to achieve the minimum of 4.0 IPs (Nielen 
et al. 2007). However, these considerations can-
not be directly extended to analysis without PRS, 
in which the chromatographic identifi cation pa-
rameter is missing.
The LC-TOFMS methods presented in this 
thesis were the fi rst to involve accurate mass-
based identifi cation against a comprehensive da-
tabase in a high-throughput manner in biologi-
cal samples. Although some LC-TOFMS screen-
ing methods have been published earlier (Zhang 
et al. 2000a, Maizels and Budde 2001, Nielen 
et al. 2001), those methods were limited to a 
low number of substances and lacked the da-
ta processing properties necessary for high-
throughput analysis. The success of the present 
methods was based on the unique approach of 
a post-run reverse target database search (Ger-
gov et al. 2001a), optimised extraction and chro-
matography, and the improved properties of the 
modern orthogonal acceleration TOFMS analys-
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ers, featuring accurate mass analysis over a wide 
dynamic range. From the vast amount of full-
spectrum data gathered during an LC-TOFMS 
run, relevant information can be retrieved imme-
diately, or afterwards if a new question is posed. 
Hence, although clearly being target screenings, 
the present methods possess similar potential for 
systematic toxicological analysis as those that 
involve the IDA approach (Decaestecker et al. 
2000). When LC-TOFMS analysis is based on ac-
curate molecular mass, isotopic pattern, metab-
olite pattern and chromatographic RT, very reli-
able identifi cation is obtained, fulfi lling the re-
quirements of confi rmation analysis. However, if 
the appropriate PRS is not available, the result 
should be considered tentative and confi rmed 
by another independent technique. The current 
developments in QTOF-MS technology obvious-
ly allow an analogous screening procedure to 
be developed, but include an additional confi -
dence level for identifi cation of unknown com-
pounds based on CID and fragmentation predic-
tion (Sweeney 2007, Hill et al. 2008, Stranz et 
al. 2008).
Some scientists think that the chances of 
fi nding the identity of an unknown compound 
increase with the total number of reference 
spectra in the database (Aebi and Bernhard 
2002). Thurman et al. proposed a scheme for us-
ing LC-TOFMS with a very large database search 
for pesticide residues in tomato skins (Thurman 
et al. 2005). The method fi rst involved initial de-
tection of a possible unknown pesticide in ac-
tual marketplace vegetable extracts by using ac-
curate mass and by generating empirical formu-
lae, then searching either the Merck Index data-
base on CD (10,000 compounds) or the ChemIn-
dex (77,000 compounds) for possible structures. 
Subsequently, an ion-trap MS instrument was 
required to measure MS/MS spectra, followed 
by fragment ion identifi cation using chemical 
drawing software and comparison with accu-
rate-mass ion fragments. Finally, verifi cation was 
performed with authentic standards, if available. 
Based on the three examples provided, the ap-
proach is innovative, but rather laborious.
Polettini et al. further extended the approach 
of LC-TOFMS screening with very large databas-
es. They used capillary electrophoresis (CE) for 
separation, and utilised a subset of the large 
PubChem Compound database (National Insti-
tutes of Health, USA) as a reference database 
(Polettini et al. 2008). This database contains ap-
proximately 50,500 compounds, including bio-
logically active small molecules, pharmaceutical 
and illicit drugs, pesticides and poisons. The av-
erage number of hits with identical chemical for-
mula was 1.82 ± 2.27, with a median of one 
and range from one to 39. However, the prob-
ability of a search retrieving different entries with 
identical chemical formula was higher than with 
smaller databases. The authors acknowledged 
that additional information, such as history or 
circumstantial data, concomitant presence of 
parent drug and metabolite, selective sample 
preparation, liquid chromatographic retention, 
and CE migration behavior, must be used in or-
der to tighten the focus of the search.
Kind and Fiehn studied accurate mass meas-
urement and isotopic pattern in the fi eld of me-
tabolomics (Kind and Fiehn 2006). Metabolomics 
tries to identify and quantify all metabolites in a 
given biological context. Generating more than 
1.6 million molecular formulae in a range of 0-
500 Da while strictly observing mathematical 
and chemical rules, they concluded that a mass 
spectrometer capable of 3 ppm mass accuracy 
and 2% error for isotopic abundance patterns 
outperforms mass spectrometers that have less 
than 1 ppm mass accuracy as well as hypotheti-
cal mass spectrometers with 0.1 ppm mass accu-
racy that do not include isotope information in 
the calculation of molecular formulae (Kind and 
Fiehn 2006). This fi nding, though based on a dif-
ferent analytical context, supports a greater sig-
nifi cance for isotopic pattern determination, as 
was also found in the present thesis.
In forensic and clinical drug analysis, the use 
of accurate mass measurement with very large 
databases may be feasible in instances where 
much effort and time have to be put into solving 
a single important case. However, high-through-
put screening that focuses on the prevalent 
drugs and poisons, as described in this thesis, 
has shown its applicability in practice. In Finland, 
roughly 80% of fatal poisonings are due to only 
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20 different drugs. The use of very large databas-
es necessarily results in a number of false posi-
tive fi ndings that require extra resources in terms 
of interpretation and time-consuming confi rma-
tion analyses.
Despite the immense value of reliable broad-
spectrum identifi cation, many application are-
as are essentially dependent on quantitative re-
sults, threshold values or cut-off limits (Wennig 
2000). The performance of single-calibrant LC-
CLND has been extensively studied in terms of 
linear range, accuracy and reproducibility. The 
linear range for diverse compounds via fl ow in-
jection ranged from 0.05 to 5 mM nitrogen, and 
the absolute response exhibited an average er-
ror of <10% among the compounds (Shah et 
al. 2000a). In another study, the response was 
found to be close to quantitative, depending 
on structures, with a variation of 10-20% when 
compounds contained isolated nitrogen atoms 
(Yan et al. 2007). Regarding compounds with 
adjacent nitrogen atoms connected by a single 
bond, e.g. triazoles or pyrazoles, the CLND re-
sponse was highly structure-dependent. In these 
cases, a structurally similar calibration compound 
should be used in quantifi cation. The day-to-day 
reproducibility of calibration curves remained 
constant at least for 15 days (Bhattachar et al. 
2006), and the long-term reproducibility based 
on indole calibrant peak area proved to be ap-
proximately ±10% (Lane et al. 2005). Anoth-
er study indicated that the caffeine calibration 
curve was stable for longer than one week of 
continuous use, but the use of a control sample 
of caffeine within a sample set was recommend-
ed (Corens et al. 2004). These fi ndings suggest 
that LC-CLND analysis is feasible in the combina-
torial chemistry environment. The studies of the 
present thesis widened the scope of LC-CLND to 
biological material, showing the robustness of 
the method with more diffi cult samples. Here, 
calibration was performed at the beginning of 
each run, and the standards were included again 
at the end of each sample set for controlling the 
stability of calibration.
Nitrogen specifi city limits the use of mobile 
phases in LC-CLND analysis. Reversed phase LC 
at acidic pH has been commonly used in separa-
tion because of the lack of volatile, nitrogen-free 
bases. The organic phase was generally metha-
nol or isopropyl alcohol since acetonitrile cannot 
be used with LC-CLND. However, when using 
isopropyl alcohol, the back-pressure can rapidly 
increase too high, particularly when small par-
ticle size LC columns are involved. Trifl uoroace-
tic acid has been used as an organic modifi er in 
the LC for improving the separation of carboxy-
lic acids, and it was also found to provide more 
effi cient mass transfer of basic compounds with 
amine groups, resulting in reduced peak tailing 
(Chan and Fujinari 2004). Mobile phase fl ow rate 
in LC-CLND should be less than 0.4 ml/min (Nus-
baum et al. 2002). Because of the limitations de-
scribed above, the optimisation of LC separation 
is challenging. In the present thesis, chromato-
graphic optimisation software, particularly Dry-
Lab, were used to facilitate LC method develop-
ment for separating basic lipophilic drugs. How-
ever, the separation is always a compromise be-
tween the run time, sensitivity and resolution.
Sample preparation for LC-CLND bioanalysis 
is a demanding task. A complex biological ma-
trix does not allow samples to be injected directly 
into the system, and all sample preparation pro-
cedures necessarily affect the recovery of drugs. 
Protein precipitation with methanol has been 
used in an LC-CLND analysis of plasma and urine 
samples (Deng et al. 2004). In the present the-
sis as well, protein precipitation was investigated 
during the method development stage, but the 
analytical background from the matrix was too 
high and prevented sensitive detection. SPE has 
been applied only in a single report, for the de-
termination of imidacloprid in fruits and vegeta-
bles (Ting et al. 2004). The extraction recovery 
for various sample materials was relatively con-
stant at 90% with an RSD of only 8%, but CLND 
was used solely as a nitrogen-selective detector. 
In bioanalytical method validation, extraction re-
covery has not been among the validation pa-
rameters regarded as essential as long as the da-
ta for LOQ or LOD, precision and accuracy (bias) 
are acceptable (Peters et al. 2007). This is due 
to the fact that an internal standard, preferably 
deuterium-labelled, compensates for the chang-
es in recovery. Single-calibrant LC-CLND applied 
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to bioanalysis sets new challenges for developing 
robust extraction methods with high precision, 
as well as for the prediction of extraction recov-
eries based on the analyte structure.
 The time factor – the third dimension of 
quality – presumes that at least the preliminary 
results of an investigation are completed within 
a reasonable period of time, which varies from a 
few hours in clinical toxicology to a few weeks in 
forensic science. It is well understood that rare 
research chemicals for basic research must often 
be solicited from a colleague scientist, but this 
should not be the case with offi cial forensic and 
clinical work. While the search for an organisa-
tion willing to provide professional laboratories 
with a rapid access to PRS of drugs is underway, 
the laboratories are obliged to develop analysis 
methods that are less dependent on the refer-
ence standards and capable of producing time-
ly analytic results with reasonable certainty. The 
present study has introduced the performance of 
one such method involving the combined use of 
LC-TOFMS and LC-CLND.
Combining LC-TOFMS and LC-CLND by split-
ting the mobile phase fl ow into both detectors 
for simultaneous identifi cation and quantifi ca-
tion may be an obvious idea. This has indeed 
been realised in combinatorial chemistry (Yurek 
et al. 2002), where the amount of sample and 
the concentration of analytes are usually suffi -
ciently high. In forensic science, too, the com-
bination of these instruments appears promis-
ing for analysing seized drugs and even impu-
rity profi les. However, the sensitivity of CLND is 
considerably lower than that of TOFMS, and this 
may cause incompatibility problems in bioanaly-
sis, as shown earlier (Deng et al. 2004). In addi-
tion, CLND is perhaps too complex to be used 
solely as a nitrogen-selective detector without 
utilizing its N-equimolar response. A feasible ap-
proach in bioanalysis would involve quantitative 
analysis by LC coupled with diode-array UV de-
tection (Pragst et al. 2004), exploiting the stable 
calibration properties of the technique, and add-
ing CLND to the system in cases where PRS are 
not available. This would allow, for example, the 
determination of important metabolites togeth-
er with their parent drugs, which would signifi -




Urine drug screening for drugs by positive ion 
LC-TOFMS, based on a large target database of 
exact monoisotopic masses, metabolic patterns, 
and LC retention times, if available, proved to be 
feasible in forensic toxicological practice. The iso-
topic pattern (SigmaFit) was taken into use for 
the fi rst time as part of a routine MS database 
search, and matching of the theoretical calcu-
lated isotopic pattern against the measured pat-
tern further improved, revealing the correct mo-
lecular composition from a mass spectrum. The 
automated acquisition of correct SigmaFit values 
and accurate masses were proven over a wide 
dynamic range, the mean mass error being 2-3 
ppm. The data obtained in this study justify the 
use of the limit values of 0.03 and 10 ppm for 
SigmaFit and mass tolerance, respectively. The 
present approach makes tentative identifi cation 
possible in urine drug screening without imme-
diate need for PRS. Additional proof can be ob-
tained from the interpretation of MS spectra af-
ter CID experiments (I, II).
Qualitative analysis by LC-TOFMS followed 
by quantitative analysis by single-calibrant LC-
CLND allowed the instant characterisation of 
seized material for both scheduled and design-
er drugs without PRS, with practically unlimited 
potential for updating the target database with 
new compounds. Possessing equimolar response 
to nitrogen, LC-CLND allows quantitative analy-
sis of drugs without access to PRS.
The mean relative difference between results 
of LC-CLND and the reference methods was only 
11%, suggesting that the accuracy of quantifi -
cation is appropriate for use in forensic science 
(III).
Single-calibrant LC-CLND analysis proved to 
be feasible for basic lipophilic drugs in plasma 
and whole blood samples in a toxicological con-
text following establishment of the mean extrac-
tion recovery. The results obtained by LC-CLND 
without PRS deviated on average 20% from the 
certifi ed reference values of profi ciency test sam-
ples. As exemplifi ed by the analysis of tramadol 
and its main metabolites, LC-CLND was capa-
ble of producing clinically relevant concentration 
data down to therapeutic levels in 5 ml plasma 
samples. Further attention should be paid to de-
veloping generic extraction methods with steady 
recovery and utilisation of model compounds for 
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